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ABSTRACT
Thyroid hormone receptor (TR) is responsible for mediating the expression of
genes involved in growth, development, and homeostatic regulation, in response
to thyroid hormone. There are two main subtypes of TR, TRα1 and TRβ1, that
mediate these physiological processes. Dysregulation of TR mediated processes
is a contributing factor in disease pathology. Our prior studies show that TR is
shuttled rapidly between the nucleus and cytosol, while localizing primarily to the
nucleus. TRα1 contains two nuclear localization signals (NLSs) that act together
to confer strong nuclear localization, while TRβ1 only contains one NLS (NLS-1).
Recently, we found that the intracellular localization of TR is regulated, in part, by
post-translational modification of lysines within NLS-1 by acetylation. We
constructed GFP or mCherry-tagged TRα1 and TRβ1 acetylation-mimic and
nonacetylation-mimic (unable to be endogenously acetylated) expression
plasmids, transfected them into HeLa cells, and used fluorescence microscopy to
determine the nuclear/cytosolic (N/C) ratio of the mutant receptors by measuring
fluorescence intensity. Data show that the TR acetylation mimic has a
significantly lower N/C ratio compared to wild-type TR, indicating a striking
decrease in nuclear localization, whereas the TR nonacetylation mimic’s N/C
ratio was the same as wild-type TR. Previously, we showed that TR nuclear
import is mediated by importins 7, β1, and α1. We hypothesized that acetylation
state alters either TR’s ability to bind importins or its intranuclear mobility, and
that inhibition of the acetyltransferase CBP/p300 would lead to enhanced TR
nuclear localization, while inhibition of the deacetylase SIRT1 would lead to TR
cytoplasmic localization. Using GFP-Trap co-immunoprecipitation, we found that
importins 7, β1, and α1 interact with both the TRα1 acetylation and
nonacetylation mimics, suggesting that the TRα1 acetylation mimic’s decreased
nuclear localization is due to factors other than reduced importin binding.
Intriguingly, fluorescence recovery after photobleaching (FRAP) revealed that the
GFP-TRα1 nonacetylation mimic has a significantly slower rate of recovery than
wild-type TRα1, suggesting that this reduced mobility correlates with greater
nuclear retention. In contrast, the GFP-TRα1 acetylation mimic had the same
rate of recovery as wild-type TRα1. Lastly, pharmacological inhibition of
CBP/p300 by C646 increased GFP-TRβ1’s nuclear localization in a dosedependent manner (GFP-TRβ1 has a slight cytosolic population due in part to
having one NLS); however, inhibition of SIRT1 by EX-527 did not alter GFPTRα1’s localization. Taken together, these data provide further evidence that
acetylation plays a key regulatory role in TR shuttling and retention and extends
our understanding of how acetylation interplays with TR-regulated processes of
growth and development.
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Chapter 1: General Introduction
The thyroid hormone receptors (TRs), TRα and TRβ, play an important role in the
normal development and function of virtually every vertebrate tissue (Mendoza and
Hollenberg 2017; Rosen and Privalsky 2011). The TRs are encoded by the genes THRA
and THRB, which produce a diverse array of TR protein subtypes and truncated forms
via alternative mRNA splicing and internal initiation codons (Anyetei-Anum, et al. 2018;
Tovo-Neto, et al. 2018). TRs mediate the action of thyroid hormone through four types of
signaling pathways, including the canonical type 1 pathway in which liganded TR directly
binds DNA. Types 2 to 4 describe TR’s indirect influence on DNA expression by either
binding to chromatin associated proteins or induction of a signaling cascade at the
plasma membrane (Flamant, et al. 2017). The predominant TR subtypes examined in
this thesis research are TRα1 and TRβ1. These two subtypes are typically composed of
nuclear localization signal (NLS) and nuclear export signal (NES) motifs that direct the
bidirectional transport of TR through the highly selective nuclear pore complex (NPC)
(Çağatay and Chook 2018; Mavinakere, et al. 2012; Subramanian, et al. 2015). The NLS
is mostly composed of the basic amino acid residues lysine and arginine, whereas the
NES is composed of hydrophobic residues such as leucine (Mavinakere, et al. 2012).
Recent investigation of TR intracellular transport has revealed the specific importins that
direct TR nuclear import (Roggero, et al. 2016). Interestingly, certain truncated forms of
TRα1 protein produced by internal translation initiation of TRα1 mRNA can localize to
the mitochondria (Anyetei-Anum, et al. 2018). The discovery that TRα1 is posttranslationally modified by acetylation within its NLS (Sanchez-Pacheco, et al. 2009), led
to our hypothesis that TRα1 acetylation alters the fine balance between nuclear import,
export, and retention of the receptor. It is evident that acetylation plays an important role
in TRα1’s nuclear localization (Anyetei-Anum 2016), although the importance of
acetylation on other TR subtypes and its functional significance remain unknown.
1

Nuclear Receptor Acetylation
Post-translational modifications (PTMs) are integral components of biological
processes, including enzymatic reactions, gene expression, and protein-protein
interactions (Csizmok and Forman-Kay 2018). There are well over 600 unique PTMs
that have been identified, including phosphorylation, ubiquitination, sumoylation,
methylation, and acetylation (Cuijpers and Vertegaal 2018; Han, et al. 2018). Any protein
in the proteome can be modified following, or during, translation and the different types
of modifications can alter a protein’s charge state, hydrophobicity, conformation and
stability (Han, et al. 2018). All 20 primary amino acids can be subject to at least one
PTM, and the flanking residues around a particular amino acid determines its probability
for a particular PTM (Doyle and Mamula 2001). Post-translational acetylation of lysine
residues will be the primary focus of the current chapter.
There are two forms of acetylation: 1) an irreversible N-terminal acetylation that
occurs early during a protein’s translation at the α-amino position of the first amino acid
to preserve its stability, protein-protein interactions, or subcellular localization; and 2)
once a protein is properly localized, a reversible acetylation of key lysine residues at the
ε-amino group can occur enzymatically or spontaneously to influence its interactions,
function, localization, and degradation (Ali, et al. 2018). In both forms, the metabolite
acetyl-coenzyme A transfers an acetyl group that is covalently conjugated to either the
N-terminus α-amino group of a protein substrate, or to the ε-position of the lysine side
chain within a protein to neutralize the position’s positive electrostatic charge (Ali, et al.
2018; Drazic, et al. 2016; Farria, et al. 2015; Wang, et al. 2011). A large information gap
persists between these two forms of acetylation, with lysine acetylation at the forefront
as an essential regulatory modification in several cellular pathways (Drazic, et al. 2016).
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Generally, reversible acetylation of lysine residues is catalyzed by lysine
acetyltransferases (KATs) and lysine deacetylases (KDACs) in both the nucleus and
cytoplasm (König, et al. 2014; Simic, et al. 2015). There are three major KAT families:
GCN5 (general control nonderepressible 5)-related N-acetyltransferases (GNATs)
(including GCN5, PCAF, ELP3, HAT1, and HPA2), the MYST (MOZ, YBF2/SAS3, SAS2,
TIP60), and the CBP (CREB, cyclic-AMP response element binding protein) / p300
(adenoviral E1A-associated protein of 300 kDa) family (Cortopassi, et al. 2016; Drazic,
et al. 2016; Milite, et al. 2015). Among the three KAT families, CBP/p300 has nuclear
receptor related KAT activity; targeting a number of nuclear receptors including the
androgen receptor (AR) (Thomas, et al. 2004), the estrogen receptor (ER) (Y. Cui, et al.
2004; Wang, et al. 2001), the farnesoid X receptor (FXR) (Kemper, et al. 2009),
steroidogenic factor 1 (SF-1) (Chen, et al. 2005), retinoid X receptor (RXR) (Zhao, et al.
2007), TRβ1 (Lin, et al. 2005), and TRα1 (Sanchez-Pacheco, et al. 2009). TRβ1 was
found to be transiently acetylated due to recruitment of the coactivator p300 in response
to thyroid hormone (T4) (Lin, et al. 2005). TRα1 was observed to be acetylated in vitro by
CBP in response to thyroid hormone (T3) at the specific lysine residues 130, 134, and
136. Acetylation of TRα1 remained even after 36 h incubation with T3 (SanchezPacheco, et al. 2009). The CBP/p300 recognition motif has been reported to be a serine
or glycine residue preceding the acetylated lysine (Bannister, et al. 2000; Kemper, et al.
2009). The CBP/p300 family members follow a “hit and run” (Theorell-Chance)
mechanism of action (Ali, et al. 2018; Cortopassi, et al. 2016; Smith and Denu 2009).
The “hit and run” mechanism is an ordered reaction in which the intermediate complex
exists for a brief period. The intermediate complex is the binding of an acetylated
cofactor, such as the acetyl-coenzyme A, and a nuclear receptor to the active site of
CBP/p300.
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Deacetylases are comprised of two major families: the classical KDACs and the
sirtuins (Cortopassi, et al. 2016; Drazic, et al. 2016; Whittle, et al. 2007). KDACs and
sirtuins are mechanistically and structurally distinct (Ali, et al. 2018). Sirtuins have
attracted increasing attention for their role in nuclear receptor deacetylation (W. Cui, et
al. 2016; Kemper, et al. 2009). The sirtuin deacetylase activity requires the oxidized form
of nicotinamide adenine dinucleotide (NAD+) as a cofactor, and the reaction begins with
a concerted and highly dissociative displacement reaction. Next, the formation of an
intermediate dependent on water occurs, and then the reaction ends with the collapse of
this intermediate to yield the reduced form of nicotinamide adenine dinucleotide (NADH)
and deacetylated lysine (Fig. 1) (Ali, et al. 2018; Cortopassi, et al. 2016). Among the
seven members of the mammalian sirtuins (SIRT1-SIRT7), SIRT1 has strong regulatory
effects on nuclear receptors, deacetylating the estrogen-related receptor α (Wilson, et al.
2010), FXR (Kemper, et al. 2009), the glucocorticoid receptor (GR) (Suzuki, et al. 2017),
and TRβ1 (Suh, et al. 2013). SIRT1 overexpression triggers TRβ1 deacetylation and
results in T3 and ubiquitin-dependent turnover of TRβ1 (Suh, et al. 2013).
Previously, nuclear receptors had been shown to form multiprotein complexes
with coregulatory proteins that possess either KAT or KDAC activity, but whether they
acted as substrates for these coregulatory proteins remained unknown. By using an
array of molecular biology techniques including substitution mutation, reporter gene
assay, and coimmunoprecipitation assays, the laboratory of Dr. Richard G. Pestell was
the first to provide evidence of androgen and estrogen receptor acetylation (Fu, et al.
2002; Wang, et al. 2001). The early finding that the androgen and estrogen receptors
serve as direct targets of KATs prompted the analysis of TRβ1 acetylation by Dr. Paul J.
Davis and coworkers. They showed that TRβ1 acetylation occurs within the hinge
domain at residues K184, K188, and K190 in human TRβ1; and the process of TRβ1
acetylation requires thyroid hormone-directed MAPK (mitogen-activated protein kinase)
4

Figure 1. Enzymatic action of the acetyltransferase CBP/p300 and the sirtuin
deacetylases. The letter R denotes a protein side chain. The letters O, N, S, and
H represent the chemical elements oxygen, nitrogen, sulphur, and hydrogen,
respectively. The three main acetyltransferase families (GNATs, MYST, and
CBP/p300) follow the same acetyltransferase reaction in which the transfer of the
acetyl group on acetyl-CoA (acetyl-coenzyme A) to the epsilon (ε) amino group of
lysine takes place. The deacetylase reaction of sirtuins begins with the removal
of the acetyl group on lysine, dependent on the cofactor NAD+, then formation of
an intermediate dependent on water (H2O) occurs (blue indicates the oxygen
donated from water). The reaction ends with the collapse of this intermediate,
yielding NADH and deacetylated lysine.
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activity, but not serine phosphorylation of TRβ1 by MAPK (Lin, et al. 2005). Recently, Dr.
Paul Webb’s laboratory reported that TRβ1 is a substrate for SIRT1 (Suh, et al. 2013).
To investigate whether SIRT1 interacts with TRβ1, they used human embryonic kidney
(HEK) 293 cells transfected with affinity tagged versions of SIRT1 (Flag) and TRβ1
(Myc). They showed co-precipitation of SIRT1 with TRβ1 using either anti-Flag or antiMyc antibodies; furthermore, co-immunoprecipitation assays in HepG2 liver cells stably
expressing TRβ1 showed that SIRT1 co-precipitated with TRβ1. For both instances, coprecipitation was independent of T3. Yet, the physiological consequence of TRβ1/SIRT1
interactions remain unclear (Suh, et al. 2013).
Work by Dr. Aurora Sánchez-Pacheco and colleagues established that human
TRα1 is acetylated at residues K130, K134, and K136, also located within the hinge
domain (Sanchez-Pacheco, et al. 2009). To determine this, GH4C1 (rat pituitary) cells
expressing endogenous TRα1 were treated for 24 h with either T3 or T3 in combination
with SAHA (suberoylanilide hydroxamic acid), a deacetylase inhibitor. Acetylated TRα1
was detected via immunoprecipitation using a TRα1-specific antibody, indicating that
thyroid hormone induced acetylation of wild-type TRα1 in vivo. Acetylation was
abolished on a TRα1 mutant with lysine to arginine substitutions, suggesting that
acetylation only occurs on the residues K130, K134, and K136 in human TRα1 (Fig. 2).
Also, the TRα1 lysine to arginine substitution mutant showed increased binding to DNA.
The substitution mutant could not initiate transcription due to an inability to recruit
transcriptional coactivators; therefore, a direct functional role of acetylation on TRα1
ligand-dependent transcriptional activation or repression could not be established. This
is because mutation of the acetylated residues also altered ligand binding and
association with transcriptional coregulatory proteins (Sanchez-Pacheco, et al. 2009). It
is worth noting that a TRα1 lysine to glutamine substitution mutant (acetylation mimetic
mutant) was not used in their study.
6

Figure 2. TRα1 and TRβ1 functional domains and acetylation sites. The letters
SKRVLA represent the first letter code of the amino acids serine, lysine, arginine,
valine, leucine, and alanine, respectively. The two terminal domains on the far
left and right of this figure play a direct role in ligand mediated transcription. The
A/B domain is responsible for activating transcription in the absence of ligand
and the LBD is responsible for activating transcription in the presence of ligand.
The hinge, NLS-containing, domain connects the DBD and LBD together and
also provides structural flexibility.
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Summary of Thesis Contents and Specific Aims

TR’s subcellular localization is an important component of the regulation of genes
responsible for growth and development. Our prior studies have built a model of this
transport activity. We showed that TR is a nucleocytoplasmic shuttling protein (Bunn, et
al. 2001), and that TR nuclear export is mediated by multiple exportins (Grespin, et al.
2008; Subramanian, et al. 2015). Recently, we have found the specific importins that
directly mediate TR nuclear import (Roggero, et al. 2016). The goal of this thesis
research is to extend our prior finding that acetylation may play an important role in
regulating TR nucleocytoplasmic transport (Anyetei-Anum 2016). Presented in this
thesis is an in-depth published literature review of the thyroid hormone receptor and it’s
subcellular localization in target tissues (Anyetei-Anum, et al. 2018). Next, this thesis
research was devoted to examining the relationship between acetylation and the factors
that play a role in TRα1 and TRβ1’s transport pathway.

The following four specific aims were investigated in this thesis research:
1. Determine if acetylation alters TR’s subcellular localization.
2. Assess the impact of acetylation on TR’s ability to bind importins.
3. Elucidate the influence of acetylation on TR’s intranuclear mobility.
4. Reveal the cellular compartment in which acetylation occurs.
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Chapter 2: Published Manuscript from Thesis Research

Thyroid hormone receptor localization in target tissues

Cyril S. Anyetei-Anum, Vincent R. Roggero and Lizabeth A. Allison
Department of Biology, College of William and Mary, Williamsburg, Virginia, U.S.A.

Correspondence should be addressed to: L. A. Allison, Department of Biology,
College of William and Mary, P.O. Box 8795, Williamsburg, VA, 23185, U.S.A.
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Abstract
The thyroid hormone receptors, TR1, TRβ1, and other subtypes, are members of the
nuclear receptor superfamily that mediate the action of thyroid hormone signaling in
numerous tissues to regulate important physiological and developmental processes.
Their most well-characterized role is as ligand-dependent transcription factors; TRs bind
thyroid hormone response elements in the presence or absence of thyroid hormone to
facilitate the expression of target genes. Although primarily residing in the nucleus, TR1
and TRβ1 shuttle rapidly between the nucleus and cytoplasm. We have identified
multiple nuclear localization signals and nuclear export signals within TR1 and TRβ1
that interact with importins and exportins, respectively, to mediate translocation across
the nuclear envelope. More recently, enigmatic cytoplasmic functions have been
ascribed to other TR subtypes, expanding the diversity of the cellular response to thyroid
hormone. By integrating data on localization signal motifs, this review provides an
overview of the complex interplay between TR’s dynamic transport pathways and thyroid
hormone signaling activities. We examine the variation in TR subtype response to
thyroid hormone signaling, and what is currently known about regulation of the variety of
tissue-specific localization patterns, including targeting to the nucleus, the
mitochondrion, and the inner surface of the plasma membrane.

Introduction

Thyroid hormone is essential for many diverse processes in nearly all vertebrate tissues,
and abnormal thyroid hormone signaling underpins several human diseases (Chen, et
al. 2013; Kim and Cheng 2013; Laudet and Gronemeyer 2002; Mendoza and Hollenberg
2017; Mondal, et al. 2016; Mullur, et al. 2014; van der Spek, et al. 2017). Much of thyroid
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hormone action is mediated by the thyroid hormone receptors (TRs), members of the
nuclear receptor superfamily that act as ligand-dependent transcription factors. By
modulating the transcription of target genes in response to ligand, TRs play key
physiological roles in the regulation of many aspects of development, growth, and
metabolism, including regulation of mitochondrial activity (Bernal 2017; Flamant and
Gauthier 2013; Pascual and Aranda 2013; Skah, et al. 2017; Vella and Hollenberg 2017;
Wrutniak-Cabello, et al. 2017). Thyroid hormone signaling is typically classified into two
distinct pathways, nongenomic and genomic; however, these designations do not fully
capture the subtleties of thyroid hormone action. To address the complexity of thyroid
hormone signaling, a more precise nomenclature has recently been formulated
(Flamant, et al. 2017). In this new classification scheme, four types of thyroid hormone
signaling are defined: type 1 is the canonical pathway in which liganded TR binds
directly to DNA; type 2 describes liganded TR tethered to chromatin-associated proteins,
but not bound to DNA directly; type 3 suggests that liganded TR can exert its function
without recruitment to chromatin in either the nucleus or cytoplasm; and type 4 proposes
that thyroid hormone acts at the plasma membrane or in the cytoplasm without binding
TR, a mechanism of action that is emerging as a key component of thyroid hormone
signaling (Davis, et al. 2016; Kalyanaraman, et al. 2014).
The biological effect of thyroid hormone in a given tissue depends on a number of
factors: the amount of available hormone, the levels of different TR subtypes and their
post-translational modifications, the type of heterodimerization partner, and their
interaction with corepressors and coactivators (Morte and Bernal 2014). In addition,
accurate translocation of TRs from their synthesis in the cytosol to their ultimate
destination is essential for maintaining proper cellular functions and activities (Bonamy
and Allison 2006; Bonamy, et al. 2005; Bondzi, et al. 2011; Fernandez-Majada, et al.
2007; Wang and Li 2014). The thyroid hormone receptors are remarkably dynamic
12

proteins. Although primarily residing in the nucleus TR1 and TR1 shuttle rapidly
between the nucleus and cytoplasm, and recent characterization of TR1 isoforms with
cytoplasmic functions adds a surprising twist to the intricacies of the receptor’s
subcellular trafficking. The fine balance between nuclear import and export of TRs has
emerged as a critical control point for modulating thyroid hormone-responsive gene
expression (Roggero, et al. 2016; Subramanian, et al. 2015), while an additional layer of
complexity is added by multiple modular, often overlapping, functional domains. General
understanding of nuclear localization signal (NLS) and nuclear export signal (NES)
structure, mitochondrial and membrane targeting signals, and how these motifs are
regulated will assist in refining understanding of the mechanism of action of TRs. In this
review we will focus on mechanisms regulating the journey of TR from its site of
synthesis in the cytoplasm to its final localization in target tissues, and how the receptor
integrates gene expression across multiple levels in the cellular response to hormone.
Before considering the cellular response to thyroid hormone, it is important to first
examine the pathway by which thyroid hormone reaches target tissues and gains access
to its intracellular receptors.

Thyroid hormone signaling

Thyroid hormone is produced through a feedback loop that includes the hypothalamus,
pituitary, and thyroid gland, commonly referred to as the hypothalamic-pituitary-thyroid
(HPT) axis (Medici, et al. 2015; Mendoza and Hollenberg 2017). The HPT axis involves
a series of signal transduction cascades, where a signal sent from the hypothalamus
eventually arrives at the thyroid gland, triggering release of thyroid hormone. In the
circulatory system, the majority of total 3,5,3′,5′-L-tetraiodothyronine (thyroxine, T4) and
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3,5,3′-L-triiodothyronine (T3) are bound with three different thyroid hormone carrying
proteins: thyroxine-binding globulin, transthyretin, and human serum albumin (Mondal, et
al. 2016; Pappa, et al. 2015). Upon reaching the target tissue, thyroid hormones enter
cells via uptake through specific membrane transporters, including the monocarboxylate
transporters MCT8 and MCT10 (Abe, et al. 2012; Bernal, et al. 2015). The most
extensively characterized transporter, MCT8, transports thyroid hormone exclusively and
preferentially binds T3; however, secondary thyroid hormone transporters have been
described that can compensate for loss of MCT8 expression, including the heterodimeric
L-type amino acid transporters (LATs), LAT1 and LAT2, and the organic aniontransporting polypeptide (OATP) family (Mendoza and Hollenberg 2017).
Once in the cell, the intracellular concentration of thyroid hormone can be modified
by the action of a suite of deiodinases. The prohormone T4 can be converted to the
physiologically active hormone T3, or inactivated via conversion to 3,3′,5′- Ltriiodothyronine (reverse T3, or rT3) within the cell. T3 and rT3 can be modified to form the
physiologically active 3,5′-L-diiodothyronine (T2), or the inactive 3,3′-L-diiodothyronine
(3,3′-T2), respectively, to protect tissues from excess hormone (Dentice, et al. 2013;
Mondal, et al. 2016; Orozco, et al. 2014). Whether T4 is directly involved in mediating
gene expression remains a subject of debate. T4 is thought to primarily influence gene
expression indirectly by cross-talk with other cell signaling pathways at the plasma
membrane (Davis, et al. 2016); however, there also is accumulating evidence that T4 can
directly modulate gene expression, dependent on the TR subtype and other cellular
cofactors (Galton 2017). T3 is directly involved in mediating gene expression by binding
to TR in either the cytoplasm or nucleus of the cell (Bunn, et al. 2001). The intricate
balance between thyroid hormone production and deiodination is critical for regulation of
TR-mediated gene expression, and the dysregulation of this process may contribute to
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type II diabetes mellitus, obesity, cardiovascular disease, and some types of cancer
(Brent 2012; Kim and Cheng 2013; Ruiz-Llorente, et al. 2011).
In addition to the type 1 canonical response mediated by nuclear TRs, thyroid
hormone also has effects not exerted through the nuclear TRs; such effects were
puzzled over early on to explain observations that thyroid hormone can, in some cases,
initiate cellular responses that are too rapid to be attributed to transcription and
translation (Davis, et al. 2016; Flamant 2016). Although detailed coverage of type 4
actions of thyroid hormone is beyond the scope of this review, it is worth noting the
existence of a hormone receptor that is associated with the plasma membrane structural
protein 3 integrin, a regulator of cell-cell and cell-extracellular matrix interactions
(Cvoro, et al. 2016; Davis, et al. 2016; Lin, et al. 2016; Martin, et al. 2014; Mullur, et al.
2014). This receptor binds T3 and T4 and stimulates certain cellular responses, such as
the remodeling of the actin cytoskeleton that is a vital component of brain development
in neurons and glial cells (Leonard and Farwell 1997), and changes in the morphology of
breast cancer cells (Flamini, et al. 2017). The 3 integrin-associated receptor has two
thyroid hormone binding sites, S1 and S2, that lead to activation of the
phosphatidylinositol 3-OH kinase (PI3K) and ERK1/2 signaling pathways, respectively.
The receptor is structurally unrelated and has no sequence homology to nuclear TR and,
although it could be referred to as a “thyroid hormone receptor,” this nomenclature
should be avoided to prevent misconceptions about the nature of this noncanonical
receptor. Type 3 signaling, mediated by transcriptionally inactive cytoplasmic TR
isoforms, will be addressed later in this review.
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Nuclear localization and function of thyroid hormone receptors

The type 1 genomic effects of TRs are two-fold; TRs can act as repressors of specific
genes in the absence of ligand and activators of these same genes in the presence of
ligand. For some genes, the reverse is the case: unliganded TR acts as an activator,
while liganded TR is a repressor. This dual role of TRs implies constitutive nuclear
localization. Many studies early on in the field supported this restricted subcellular
distribution for TR (Andersson and Vennstrom 1997; Kumara-Siri, et al. 1986; Lee and
Mahdavi 1993; Macchia, et al. 1992; Zhang and Lazar 2000; Zhu, et al. 1998). However,
we and others have shown that even though TR1 and TR1 appear to be
predominantly nuclear at steady state, in fact, the receptors are undergoing rapid
nucleocytoplasmic shuttling in both the presence and absence of T3 (Baumann, et al.
2001; Bunn, et al. 2001), movement which can be visualized by heterokaryon assays or
fluorescence recovery after photobleaching (Grespin, et al. 2008; Subramanian, et al.
2015). Detailed investigation of TRs has revealed distinct, dynamic localization patterns
for some variants. Analysis of the intracellular localization of TRs by biochemical
fractionation, immunocytochemistry, or indirect immunofluorescence assays has proved
challenging overall, because of a lack of validated isoform-specific antibodies, and the
difficulty in detecting endogenous TR subtypes that are less abundant in cells. Many
studies have thus relied on transient transfection assays and expression of fluorescent
protein-tagged TRs. With regards to nuclear localization, in our hands, there is no
indication that overexpressing TRs leads to a more cytoplasmic localization by saturating
the capacity of cells to transport proteins into the nucleus, or that fluorescent protein tags
alter localization. For example, in transfected NIH-3T3 (mouse) cells or HeLa (human)
cells, neither of which express detectable levels of endogenous TR, both exogenous
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GFP-tagged TR1 and untagged TR1 detected by antibody staining show a primarily
nuclear distribution at steady state (Bonamy, et al. 2005; Bunn, et al. 2001).

Thyroid hormone receptor subtypes
The thyroid hormone receptors are well conserved throughout vertebrate evolution,
originating from a single TR gene early in animal evolution (Manzon, et al. 2014); and
there is evidence for nuclear TR-mediated responses to thyroid hormone in nonvertebrate lineages, including molluscs, echinoderms, cephalochordates, and ascidians
(Darras, et al. 2011; Huang, et al. 2015; Laudet and Gronemeyer 2002; Taylor and
Heyland 2017). The vertebrate thyroid hormone receptors are encoded by two genes
located on different chromosomes, NR1A1 and NR1A2, although due to ancestral gene
duplication, some nonmammalian vertebrate species, including teleost fish, have two
TR-encoding genes (Darras, et al. 2011; Galay-Burgos, et al. 2008). From these loci, a
surprisingly diverse set of TR proteins are produced, through alternative splicing,
alternative promoter usage, and internal initiation codons. Intense investigation of rodent
and human TRs continues to reveal new subtypes, while the number of subtypes
identified in other species, as of yet, is more restricted (Buchholz, et al. 2006; Kanaho, et
al. 2006; Nelson and Habibi 2008; Politis, et al. 2017). For example, chickens and ducks
have at least three subtypes (TR, TR2, TR0) (Bishop, et al. 2000); zebrafish
produces two TR variants and at least three TR isoforms that all act as functional
nuclear receptors (Darras, et al. 2011); two distinct TR transcripts and one TR
transcript have been isolated from the American alligator (Helbing, et al. 2006); and the
Atlantic halibut has two TR and two TR isoforms (Galay-Burgos, et al. 2008). The
main focus of this review is on the well-characterized mammalian receptors, in particular
TR1 and TR1.
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Not all of the mammalian TR proteins produced act as nuclear receptors, however,
and the physiological significance of many of the nonreceptor isoforms remains a subject
of investigation (Flamant and Gauthier 2013; Mullur, et al. 2014; Vella and Hollenberg
2017). What is currently known about the intracellular localization and function of the
mammalian TRs is summarized in Table 1, and further described herein. The
predominant isoforms generated by alternative splicing mechanisms include the bona
fide nuclear receptors TR1, TR1, TR2, TR3, and TR4 (Moriyama, et al. 2016;
Tagami, et al. 2010); and the nonreceptor TR variants that lack T3 binding ability, TR2,
TR3, and TRα‐E6 (Casas, et al. 2006).
TR1 has the highest expression in bone, the gastrointestinal tract, cardiac and
skeletal muscle, and the central nervous system; TR2 and TR3 are predominant in
the brain, kidney, testis, brown adipose tissue, and skeletal muscle (Guissouma, et al.
2014; Skah, et al. 2017). TRα‐E6 is expressed in all tissues tested, and can sequester
TR1 in the cytoplasm (Casas, et al. 2006). TR2 is found consistently in mammals but
not in other species. Although a dominant negative function has been attributed to
mammalian TR2, which is widely co-expressed with TR1, the physiological relevance
has remained a puzzle, particularly since it is unexplained why it would be necessary for
TR2 to counter-balance normal TR activity in mammals but not in non-mammalian
species (Vennstrom et al., 2010). There is recent compelling evidence, however, that
TR2 modulates thyrotropin releasing hormone gene expression in the hypothalamus
(Guissouma, et al. 2014). In addition, four truncated forms of TR1 (full-length, 46 kDa)
originate from alternative internal AUG translation initiation codons in TRα1 mRNA and
are named based on their molecular masses: p43 starts at the equivalent of methionine39 (Met39) in the full-length receptor, p33 starts with Met120, p30 starts with Met122, and
p28 starts with Met150 (Kalyanaraman, et al. 2014; Wrutniak-Cabello, et al. 2017) (Fig. 1).
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Finally, other truncated forms of TR, TRα1 and TRα2, are produced from an internal
promoter in intron 7; they contain only the C-terminus of the LBD and are expressed in
the brain, lung, and gut (Davis, et al. 2016; Chassande, et al. 1997). TRα1 has been
proposed as a candidate mediator of T4-binding in the cytoplasm, potentially playing a
role in regulating actin polymerization (Davis, et al. 2016).
TR1 is most abundant in the liver, kidney, and the inner ear; TR2 is predominant
in the hypothalamus, pituitary, cochlea, and retina; and TR4 is ubiquitously expressed,
with relatively high expression in the brain and kidney (Flamant and Gauthier 2013;
Hahm and Privalsky 2013; Mullur, et al. 2014; Vella and Hollenberg 2017). Other minor
isoforms of TR1 (52-kD) also exist; for example, two isoforms are alternatively
translated from TR1 mRNA, with TR3 (44.6-kD) appearing to act as a functional
receptor in rat (Flamant and Gauthier 2013), and TR∆3 (32.8-kD) functioning as a
ligand-responsive dominant negative antagonist (Williams 2000). In addition, an
elongated form of TR2, termed TR2, has been proposed to function as a nuclear
receptor in the rat pituitary gland (Zhao, et al. 2014). In this review, we will focus on the
TR and TR isoforms where intracellular localization and targeting signals have been
investigated in more detail.

Functional domains of the thyroid hormone receptor
The thyroid hormone receptor consists of four modular domains that are evolutionarily
conserved among the nuclear receptor superfamily (Fig. 1): a variable N-terminal A/B
domain, which contains a region involved in transactivation, activation function-1 (AF-1);
a central DNA binding domain (DBD) comprised of two zinc fingers; a C-terminal ligandbinding domain (LBD), which also includes dimerization interfaces and activation
function-2 (AF-2); and a linker or hinge region between the LBD and DBD that
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contributes to DNA binding, activation function and repression, ligand binding, and
corepressor interactions (Mondal, et al. 2016; Nascimento, et al. 2006; Pawlak, et al.
2012; Zhang, et al. 2017). TR1 and TR1 both contain AF-1 domains involved in the
transcriptional response to hormone; while the TR2 isoform, which differs from TR1 in
the A/B domain, has a unique hormone-independent AF-1 domain that recruits
coactivators (Tomura, et al. 1995; Oberste-Berghas, et al. 2000).

Ligand-binding domain conformation
The LBD of TR is composed of 12 -helices that form a hollow pocket lined with
hydrophobic residues. The ligand binding site is highly flexible, and the structural details
underpinning receptor activation after T3 binding are complex (Schweizer, et al. 2017).
The twelfth helix contains the ligand-dependent activation domain, AF2 (Figueira, et al.
2011). Helix 12 forms a short pivoting structure that can adopt different conformations. In
the absence of T3, helix 12 is in an extended position and the corepressor binding
groove is occupied by the corepressor nuclear receptor (CoRNR)-box helical motifs
found in silencing mediator for retinoid or thyroid-hormone receptors (SMRT) and
nuclear receptor co-repressor 1 (N-CoR1). Binding of T3 may induce a hormonedependent “mouse-trap” mechanism (Flamant 2016; Moras and Gronemeyer 1998;
Sonoda, et al. 2008), where helix 12 rotates to swing shut and close off the pocket
around T3. As a result of this conformational change, a novel docking surface forms for
interaction with LXXLL motifs (L denotes leucine; X denotes an undetermined amino
acid) of a transcriptional coactivator (Rosen and Privalsky 2011). A refinement of this
model suggests that TR helix 12 functions as a “selective gatekeeper” that actively
discriminates between different forms of corepressor even in the unliganded receptor
(Rosen and Privalsky 2009); and other models propose that rearrangements in a mobile
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part of the LBD comprising helix 3, the loop between helix 1 and helix 2, and nearby βsheets, play a greater role in ligand dissociation than repositioning of helix 12 (Martinez,
et al. 2006). Mutations that disrupt helix 12 alter corepressor specificity as well as T3mediated release of corepressors (Rosen and Privalsky 2009). Recent X-ray
crystallographic structural studies have revealed a second ligand binding site in TR
located between helices 9-11 that may interact with T4 (Souza, et al. 2014).

Nuclear import and export signals
The nuclear transport process provides a central regulatory point for coordinating cell
signaling and gene expression. Macromolecules known as nuclear pore complexes
(NPCs) are the regulatory gatekeepers of the entry and exit of nuclear proteins, and
allow for the passive diffusion of small molecules less than 40-kD (Li, et al. 2016). NPCs
are distributed throughout the nuclear envelope, embedded at sites within the luminal
space between the outer and inner membrane of the nuclear envelope (Cautain, et al.
2015; Tran, et al. 2014). They are octagonally symmetric cylindrical structures made up
of proteins termed nucleoporins or Nups, that act to anchor the NPC in the nuclear
envelope and provide interaction domains for nuclear proteins to translocate through a
central channel (Hayama, et al. 2017). The translocation of nuclear proteins through the
NPCs is typically facilitated by karyopherin -like family members (importins and
exportins), with each member performing a distinct nuclear import, export, or
bidirectional transport function (Chook and Suel 2011; Kimura and Imamoto 2014).
Our systematic characterization of nuclear export signal (NES) and nuclear
localization signal (NLS) motifs by site-directed mutagenesis has elucidated the
mechanics of TR nuclear localization (Mavinakere, et al. 2012). In depth analysis of
TR1 and TR1 structure reveals that the two subtypes both contain a classical bipartite
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NLS, named NLS-1, residing in the hinge region, and a second monopartite NLS, termed
NLS-2, located in the A/B domain of TR1 that is absent in TR1 (Fig. 1) (Mavinakere,
et al. 2012). RNAi and coimmunoprecipitation assays show that members of the importin
family of karyopherins, specifically importin 7, importin 1, and adapter importin 1
recognize these NLSs and directly mediate the nuclear import of TRs through the NPC
(Roggero, et al. 2016) (Fig. 2). In support of the importance of NLS-1 for efficient nuclear
localization, an isoform that lacks the hinge domain, TRα‐E6, has a strikingly altered
localization compared with TRα1; TRα‐E6-GFP was shown to be predominantly
expressed in the cytoplasm with minor nuclear fluorescence (Casas, et al. 2006). In
addition, TR4 is primarily localized to the nucleus, and mutation of two putative NLSs
near the hinge region results in a whole cell distribution of the receptor (Moriyama, et al.
2016).
In an earlier study, we showed that TR1 exits the nucleus through two pathways,
one dependent on the export factors CRM1 and calreticulin, and the other CRM1independent (Grespin, et al. 2008). In a subsequent study, we also identified a novel
NES in helix 12 of the ligand-binding domain of TR (NES-H12). Another novel NES motif
spans helix 3 and helix 6 (NES-H3/H6) (Mavinakere, et al. 2012) (Fig. 1). Notably, these
NES motifs are not sensitive to leptomycin B, a specific inhibitor of CRM1, suggesting
that they mediate the CRM1-independent export pathway followed by TR. Follow-up
work by RNAi has shown that multiple exportins influence TR export, including exportins
4, 5, and 7 (Subramanian, et al. 2015). Not surprisingly, the two NLSs found in TR1 act
to confer strong nuclear localization to the receptor; we hypothesize that TR1’s small
cytosolic population (Baumann, et al. 2001; Zhu, et al. 1998) may reflect an altered
balance of NLS and NES activity (Mavinakere, et al. 2012; Zhang, et al. 2017) (Fig. 3).
Although multiple NLS and NES motifs exist in a variety of nuclear proteins, how these
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multiple signals interact in collective remains unclear (Bonaldi, et al. 2003; Dai, et al.
2015; Lu, et al. 2014; Mavinakere, et al. 2012; Panayiotou, et al. 2016; Umemoto and
Fujiki 2012). Once TRs are directed into the nucleus and released from importin, they
can then interact with target genes to modulate gene expression in response to
hormone.

Thyroid hormone receptor gene activation and silencing
A multifaceted cascade of events results in binding of TRs to thyroid hormone response
elements (TREs) and culminates in the modulation of target gene expression in
response to thyroid hormone (Ayers, et al. 2014; Bernal and Morte 2013; Brent 2012;
Vella and Hollenberg 2017). Thyroid hormone receptors often heterodimerize with the
retinoid X receptor (RXR), expanding the range of T3 responsiveness for genes within
the same cell (Diallo, et al. 2007; Flamant 2016). On positive TREs, corepressors, such
as N-CoR1 or N-CoR2 (also known as SMRT) and histone deacetylase (HDAC), are
bound in the absence of ligand to TR, leading to repression of target gene expression
(Mendoza, et al. 2017; Oberoi, et al. 2011; Xu, et al. 1999). Upon ligand binding, TR
undergoes a conformational change, resulting in a new set of activator proteins bound to
the receptor, such as SRC-1 (p160/steroid receptor coactivator 1) and histone
acetyltransferase (HAT). This leads to changes in chromatin structure and the
subsequent transcription of the target gene (Dasgupta and O'Malley 2014; McKenna, et
al. 1999; Soriano, et al. 2011). In addition to unliganded TR bound to positive TREs,
chromatin immunoprecipitation sequencing (ChIP-seq) analysis of endogenous TR in
mouse liver tissue suggests that the receptor’s interaction with chromatin is highly
dynamic and that it can be recruited to chromatin in a ligand-dependent manner
(Grontved, et al. 2015). These findings align with an earlier report that used fluorescence
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recovery after photobleaching (FRAP) to show that TR1 moves rapidly within the
nucleus, and that ligand binding does not affect its mobility (Maruvada, et al. 2003). A
recent study in mice suggests that TR target genes respond to T3 based on the
availability of specific corepressors and coactivators, providing an explanation for tissuespecific responses to similar amounts of T3 (Vella, et al. 2014). In addition to activating
transcription on positive TREs, TRs can also repress gene expression, possibly by
binding to putative negative TREs in a T3-dependent manner (Bernal and Morte 2013).
In this instance, N-CoR1 and SMRT appear to play a role in determining T3-sensitivity,
suggesting that corepressors can be recruited to TR in the presence of T3 (Astapova and
Hollenberg 2013; Astapova, et al. 2011; Shimizu, et al. 2015). The mechanism remains
unclear, however, and a recent genome-wide analysis of chromatin occupancy of TRs in
neural cells does not appear to support the hypothesis that liganded TR acts directly as
a transcription repressor (Chatonnet, et al. 2013). Further, ChIP-seq studies in
hypothyroid and hyperthyroid mouse liver cells suggest that negative regulation instead
may be mediated by diminished TR recruitment in the presence of T3 (Ramadoss, et al.
2014).

Cytoplasmic Functions of the Thyroid Hormone Receptor

For many years the focus in the field was on characterizing the nuclear function of TRs,
but now their emerging roles in the cytoplasm also must be considered. Study of the
functional domains of full-length TRα1 (p46) and the truncated isoforms p43, p33, p30,
and p28 has revealed conflicting intracellular targeting signals within TRα1 that can
direct the proteins to the nucleus, mitochondria, or the inner surface of the plasma
membrane (Kalyanaraman, et al. 2014; Mavinakere, et al. 2012; Wrutniak-Cabello, et al.
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2017) (Figs.1 and 4). TRα1 p43 and p28 are targeted to the mitochondrial matrix and
mitochondrial inner membrane, respectively. The biological function of TRα1 p33
remains unknown, but p30 is post-translationally modified via palmitoylation and
colocalizes with caveolin-1 at the inner surface of the plasma membrane. Upon binding
T3 the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-protein kinase G
(PKG) signaling cascade is activated, and stimulates proliferation and survival in multiple
cell types (Hiroi, et al. 2006; Kalyanaraman, et al. 2014; Wrutniak-Cabello, et al. 2017).
Studies in diverse cells types, including human adipose-derived stem cells
(hADSC), human primary osteoblasts, mouse osteoblast-like MC3T3 cells, monkey
kidney cells (CV-1), neonatal rat ventricular myocytes (NRVM), and mouse
cardiomyocytes (HL-1), have revealed TR subtypes localized to the mitochondria,
plasma membrane, and cytoplasmic compartments in a tissue-specific manner (Carazo,
et al. 2012; Cvoro ,et al. 2016; Kalyanaraman, et al. 2014; Wadosky, et al. 2016). Of
particular interest, human ADSCs are multipotent adult stem cells with the capacity to
differentiate into adipocytes, chondrocytes, and osteocytes, and they express TR1,
TR2, and TR1 at variable levels. TR intracellular localization was investigated by
indirect immunofluorescence assay and, interestingly, all subtypes showed cytoplasmic
localization. Further examination via double immunostaining of TR1 and TR2 with a
mitochondrial marker showed a predominantly mitochondrial localization for TR1
proteins (Carazo, et al. 2012; Psarra and Sekeris 2008; Wadosky, et al. 2016). Although
western blot analysis was not performed to visualize protein size, these findings suggest
that truncated forms of TR were reliably being detected by the antibodies used in this
study.
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Mitochondrial targeting
A major compartment of thyroid hormone accumulation within the cell is the mitochondria
(Bassett, et al. 2003; Davis, et al. 2016; Psarra and Sekeris 2008; Wrutniak-Cabello, et
al. 2017). The major effect of thyroid hormone on mitochondrial activity has been
partially explained by reports of truncated TR1 variants localizing to the mitochondria of
different mammalian tissues, such as liver, brown and white adipose tissue, red and
white muscle, heart, tongue, and testis (Carazo, et al. 2012; Fumel, et al. 2013;
Wrutniak-Cabello, et al. 2017). In addition, a truncated TR (TRA1) localizes to the
mitochondria in Xenopus laevis (South African clawed frog) oocytes (Saelim, et al.
2007). TRα1 p43 is targeted to the mitochondrial matrix, while TRα1 p28 is targeted to
the mitochondrial inner membrane (Carazo, et al. 2012; Kalyanaraman, et al. 2014;
Wrutniak-Cabello, et al. 2017) (Fig. 4). TRα1 p43 displays an N-terminal deletion that
lacks NLS-2, but still possesses NLS-1 in the hinge region (Fig. 1). In contrast, TRα1
p28 displays an N-terminal deletion of the A/B domain, the DBD, and NLS-1. Neither p43
or p28 possess a canonical mitochondrial import signal (MIS). Nonetheless, sequences
within helices 5, 10, and 11 in the C-terminal LBD of p43 and p28 have been identified
that are necessary for mitochondrial import (Carazo, et al. 2012) (Fig. 1). Helix 5,
spanning amino acids 242-252 of TR1, was found to drive an atypical mitochondrial
import process independent of ATP and the mitochondrial membrane potential; whereas
helices 10-11, spanning amino acids 298-354, induced a typical mitochondrial import
process sensitive to ATP and the mitochondrial membrane potential. Whether these two
mitochondrial import sequences, MIS1 and MIS2, are functional or not, is proposed to
depend on the “permissive” role of the N-terminus of TR1 (Carazo, et al. 2012). In this
model, conformational changes of the protein, dependent on the flexibility of the hinge
region, would disrupt the functionality of NLS-1 in the hinge region and induce the
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activity of the mitochondrial import sequences (Wrutniak-Cabello, et al. 2017).
Interestingly, TR1 harbors these conserved MIS1 and MIS2 motifs and lacks NLS-2 in
the N-terminal A/B domain (Fig. 1), but there is no evidence of functionality of the MIS
motifs. It is of interest to determine the exact nature of the N-terminal A/B domain
sequence in regulating localization of TRs to the mitochondrial or nuclear compartments.

Plasma membrane targeting
Beyond type 1 genomic actions within the mitochondria, type 3 actions of TR are
primarily associated with its localization to the plasma membrane. The alternative
translation product TRα1 p30 is targeted to the plasma membrane where it is proposed
to play a key role in mediating signaling pathways involved in cell survival and
proliferation (Carazo, et al. 2012; Kalyanaraman, et al. 2014; Wrutniak-Cabello, et al.
2017). Further, there is tissue-specific variation in p30’s localization to the plasma
membrane (Kalyanaraman, et al. 2014). In murine primary osteoblasts, TRα1 p30
associates with lipid rafts (cholesterol-rich plasma membrane microdomains that contain
caveolin-1) to function as a unique signal transduction platform. In contrast, in MC3T3
cells TRα1 p30 associated with caveolin-1, nitric oxide synthase 3 (NOS3), protein
kinase G type II (PKGII), and the tyrosine kinase Src. These data point to the possibility
that TRα1 p28 localizes to the mitochondrial inner membrane following a similar
mechanism (Kalyanaraman, et al. 2014), and provide an understanding of how certain
membrane-targeted proteins interact with caveolin to reach the plasma membrane
(Hayer, et al. 2010).
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A role for posttranslational modification in TR localization

Post-translational modifications (PTMs) play a significant role in the regulation of protein
structure, enzymatic activity, stability or degradation, subcellular localization, proteinprotein interactions, and diverse cell signaling (Azevedo and Saiardi 2016; Drazic, et al.
2016; Lin, et al. 2015; Rodriguez 2014). Many amino acid side chains such as cysteine
(C), serine (S), threonine (T), and tyrosine (Y) are post-translationally modified; however,
the amino acid lysine (K) is targeted by an extremely high number of PTMs including
methylation, ubiquitination, sumoylation, and acetylation. Thyroid hormone receptors,
and other nuclear receptors, undergo PTMs that influence transcriptional activity and
subcellular localization (Abdel-Hafiz and Horwitz 2014; Cui, et al. 2004; Faresse 2014;
Lin, et al. 2005; Sanchez-Pacheco, et al. 2009). For example, the association of TRα1
p30 with the plasma membrane is mediated by palmitoylation, a post-translational lipid
modification. Consequently, it has been predicted that cysteine (Cys)254 and Cys255
palmitoylation is necessary to localize p30 to the plasma membrane (Kalyanaraman, et
al. 2014).
For nuclear TRs, phosphorylation regulates DNA binding and transcriptional
activation, and it has been shown that phosphorylation of one or more sites in TRα1
enhances nuclear retention or inhibits nuclear export but is not directly involved in
nuclear import (Nicoll, et al. 2003). Intriguingly, a recent study suggests the
phosphorylation of TRβ1 may play a role in promoting nuclear localization in serumstarved Chinese hamster ovary (CHO) cells. FLAG-tagged TRβ1 was shown to form a
cytoplasmic complex with the p85 regulatory subunit of PI3K and the Src family kinase
Lyn (Martin, et al. 2014). Complex formation was dependent on two phosphotyrosine
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motifs in the second zinc finger of TRβ1 that are not conserved in TR1. When hormone
was added, the complex dissociated, allowing PI3K activity to increase and TRβ1 to
move into the nucleus to regulate transcription. It will be of interest to extend these
studies to tracking receptor movement in live cells. The authors suggest that dramatic
shifts in localization may not be observable with GFP-tagged receptors, because the
GFP tag might interfere with PI3K association; however, their qualitative observations of
receptor distribution are consistent with the variability we see in populations of cells
expressing GFP-TRβ1. As shown in Fig. 3, GFP-TRβ1 typically has a greater cytosolic
population than GFP-TR1, and we find TR1 distributions ranging from whole cell to
primarily nuclear. For critical analysis of the fine nuances of receptor localization,
rigorous quantification of the nucleus versus cytoplasmic distribution by fluorescence
intensity measurements will be essential.
Acetylation sites that are important for transcriptional activity have been identified in
the hinge domain of TR, corresponding to K130, K134, and K136 in human TR1
(Sanchez-Pacheco, et al. 2009), and to K184, K188, and K190 in TR1 (Lin, et al. 2005).
These lysines are integral components of NLS-1 (Mavinakere, et al. 2012), suggesting
that acetylation state could have an impact on NLS activity. Whether this PTM is
important for modulating the nuclear localization of TR subtypes is under investigation.
It is known that ubiquitination of liganded TRα1 targets the receptor for rapid
proteasome-mediated degradation (Bondzi, et al. 2011). Recently, it was reported that
monoubiquitination of TR1 within its LBD results in a shift in the diffuse intranuclear
localization of TR1 toward the nuclear periphery in cardiomyocytes (Wadosky, et al.
2016). TR1 activity stimulates hypertrophy in cardiomyocytes, and although TR2 and
TR1 are present in this cell type, they lack this function. Muscle-specific ubiquitin ligase
muscle ring finger-1 (MuRF1) (Rodriguez, et al. 2015) was shown to monoubiquitinate
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TR1 in vitro; however, specific lysine sites have not yet been identified and
monoubiquitinated forms have not been detected in vivo (Wadosky, et al. 2016).
Whether polyubiquitination or monoubiquitination directly modulates TR
nucleocytoplasmic shuttling remains to be determined.
Several studies have provided evidence that sumoylation of TR plays an essential
role in fine-tuning TR regulation of gene expression. SUMO modification sites have been
identified at K283 and K389 of TR1 (positioned in NES-H3/H6); and at K50 (A/B
domain within AF1), K146 (DBD) and at K443 (near the NES-H12 motif) of TR1 (Liu, et
al. 2015; Liu, et al. 2012; Weitzel 2016). Given the proximity of the SUMO-modified
lysines to NES motifs, sumoylation is also under study for its impact on NES activity and
TR nuclear localization.
Taken together, these reports provide insights into the possible interplay of TR posttranslational modification with TR localization: palmitoylation directs p30 to the
membrane; phosphorylation promotes nuclear retention; acetylation occurs within the
hinge NLS-1; and ubiquitination and sumoylation occur within the NES-containing LBD
of TR. Although not yet reported to be post-translationally modified, TRα1 p43 contains
mitochondrial import sequences and thus has a high probability of also containing PTM
sites that modulate trafficking.

Mislocalization of thyroid hormone receptors and disease

In addition to diseases correlated with dysregulated hormone production, mutations in
TR can give rise to disease, most notably the autosomal dominant Resistance to Thyroid
Hormone (RTH) syndrome; and mutations can contribute to certain types of cancer,
including human hepatocellular carcinoma, renal clear cell carcinoma, breast cancer,
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pituitary tumor, and thyroid cancer (Astapova, et al. 2011). Early evidence to suggest
that mutated TR could be involved in carcinogenesis came from the discovery that TR1
is the cellular counterpart of the retroviral v-ErbA carried by the avian erythroblastosis
virus involved in acute erythroleukemia and sarcomas (Sap, et al. 1986). Many of these
TR mutants have lost T3 binding and transactivation capacity and some exhibit dominant
negative activity (Chan and Privalsky 2010; Conde, et al. 2006; Kim and Cheng 2013;
Lin, et al. 2013; Martinez-Iglesias, et al. 2009; Rosen, et al. 2011; Rosen and Privalsky
2009, 2011; Wojcicka, et al. 2014). The question is thus raised, does receptor
localization impact disease pathology? So far, the answer appears to be, yes. Dominant
negative TR mutants, such as v-ErbA, have been shown to localize to both the nuclear
and cytoplasmic compartments in cells (Boucher, et al. 1988), are recruited to
aggresomes, display altered transport activity and mislocalize TR1 to these cytosolic
inclusions (Bonamy and Allison 2006; Bonamy, et al. 2005; Bondzi, et al. 2011; Bunn, et
al. 2001; DeLong, et al. 2004; Takalo, et al. 2013; Zhang, et al. 2017). The altered
localization of v-ErbA appears to be enhanced by acquisition of the N-terminal viral Gag
sequence, which harbors a strong CRM1-dependent NES (DeLong, et al. 2004).
The factors that determine whether a given amino acid substitution causes
endocrine disruption or cancer remain enigmatic, particularly for changes within the LBD.
Typically, human cancers have multiple TR mutations, while single mutations are
characteristic of RTH, and it has been proposed that synergistic interactions of these
mutations strengthen the dominant negative activity (Rosen and Privalsky 2009, 2011).
RTH syndromes exist due to mutations in the respective TR isoforms, TR1 and TR1,
and the variability in symptomatic phenotype is characterized by the tissues in which
these isoforms are highly expressed (Mendoza and Hollenberg 2017; Mullur, et al. 2014;
Vella and Hollenberg 2017; Vella, et al. 2014). Clinical phenotypes of RTH include

31

elevated thyroid hormone levels, goiter, short stature, decreased weight, tachycardia,
hearing loss, attention-deficit hyperactivity disorder, decreased IQ, and dyslexia
(Bochukova, et al. 2012; Dumitrescu and Refetoff 2013; Moran, et al. 2013; Parrilla, et
al. 1991; Schoenmakers, et al. 2013). Interestingly, the highest frequency of mutations
occurs in the region corresponding to NES-H12, with another cluster of mutations
occurring within NES-H3/H6 (Fig. 1).
Except for our prior studies, there is little information on the contribution of altered
nucleocytoplasmic shuttling dynamics to the phenotype of RTH and cancer-promoting
mutants. Two of our recent findings stand out: a R26H substitution in NLS-2 of the
oncoprotein v-ErbA abrogates the activity of NLS-2, while mutagenesis studies on NESH12 point to the intriguing possibility that altered shuttling of TRβ1 may be a contributing
factor in RTH (Mavinakere, et al. 2012). Based on these data, we hypothesize that
intracellular mislocalization of TR is a crucial factor to consider in pathogenesis (Bonamy
and Allison 2006; Bonamy, et al. 2005).

Concluding remarks

Thyroid hormone receptor subtypes mediate the actions of thyroid hormone in a variety
of cellular compartments, including the nucleus, the mitochondria, and at the inner
surface of the plasma membrane (Fig. 4). Within the nucleus, TR1 and TR1 bind to
the TREs of target genes, in the presence or absence of thyroid hormone, to influence
an astonishing number of cellular processes, including cell proliferation, oxygen
consumption, protein synthesis, and carbohydrate, lipid, and vitamin metabolism. The
physiological significance of TR1 and TR1 nucleocytoplasmic shuttling may, at least
in part, be to serve as a “ferry boat” (Kolodkin, et al. 2010) to increase the rate of T3 (and
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possibly T4) nuclear entry, relative to simple diffusion through the cytosol, or to
circumvent localization of T3 to the mitochondria. Furthermore, important PTMs have
been reported that suggest an increasingly complex interplay with TR’s NLS and NES
motifs, and possibly MIS motifs, that may affect TR’s ultimate localization in target
tissues. There is a dynamic balance between nuclear import, retention, and export of
shuttling transcription factors and, in the case of TR, localization to cytosolic
compartments as well. These observations, coupled with the multiplicity of thyroid
hormone signaling within the cell, may provide important insights into the development of
treatments for RTH and some types of cancer.
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Figure 1. Thyroid hormone receptor (TR) major subtypes and localization signals. The
structural diagram (not to scale) of TR1, TR1, and TR2 shows nuclear localization
signal (NLS), nuclear export signal (NES), and mitochondrial import sequence (MIS)
motifs, where known (solid bar) or predicted (striped bar) based on sequence homology.
The positions of localization signals are indicated in relation to the respective individual
domains of TR: N-terminal A/B domain (A/B), DNA-binding domain (DBD), hinge
domain, and ligand-binding domain (LBD). The TR1 mRNA encodes several forms of
truncated TR by translation initiation from internal AUG sites encoding methionine (M);
amino acid residue numbers correspond to the position in full-length TR1.
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Figure 2. Thyroid hormone receptor nucleocytoplasmic shuttling pathway. The wellcharacterized pathway for TR1 is depicted. TR1 binds to specific importins in the
cytoplasm, as indicated. The TR1-importin complex passes through a nuclear pore
complex (NPC) embedded in the nuclear envelope into the nucleus, where the complex
is disassembled and TR1 binds to target genes. TR1 exits the nucleus through the
NPC in association with specific exportins or calreticulin (CRT)/CRM1. TR1 follows a
similar nucleocytoplasmic shuttling pathway, but nuclear import is solely mediated by the
importin α1/importin 1 complex.
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Figure 3. Distinct intracellular localization patterns for TR1 and TR1. HeLa cells
transfected with expression plasmids for green fluorescent protein (GFP)-tagged TR1
and TR1 were analyzed by fluorescence microscopy after staining for DNA with DAPI
to visualize the nucleus. GFP-TRα1 predominantly localizes to the nucleus; GFP-TR1
also localizes to the nucleus but has a slight cytoplasmic population. Scale bar, 10 m.
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Figure 4. Model for localization of TRα1 isoforms to the mitochondria, plasma
membrane, and nucleus. TR1 mRNA yields different forms of truncated TR by internal
translation initiation. Once synthesized in the cytosol, the different forms localize to
different intracellular compartments. TR1 p28 and TR1 p43 localize to the
mitochondrial inner membrane and matrix, respectively. TR1 p30 localizes to the inner
surface of the plasma membrane, where it can bind to thyroid hormone to mediate
thyroid hormone signaling. The specific localization and function of TR1 p33 remains
unknown. Full-length TR1 (TR1 p46) localizes to the nucleus where it modulates
target gene expression in response to thyroid hormone, in association with corepressors
and coactivators. Thyroid hormone enters the cell through the monocarboxylate 8 and
10 transporters (MCT8/10).
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Table 1 Cellular localization and function of mammalian TRα and TRβ isoforms
Receptors

Cellular localization

Known or hypothetical
function(s)

Nuclear

Transcriptional activation/repression

TRα (NR1A1)
TRα1
p46 (full-length)
p43

Mitochondrial matrix

Transcriptional activation/repression

p33

Unknown

Unknown

p30

Plasma membrane

Signaling cascade

Mitochondrial inner membrane

Signaling cascade

TRα2

p28

Nuclear

Possible antagonist of TR action

TRα3

Nuclear

Possible antagonist of TR action

TR ∆α1

Unknown

Possible antagonist of TR action

TR ∆α2

Unknown

Possible antagonist of TR action

TRα-∆E6

Cytoplasm

Inhibitor of TR activity

TRβ1

Predominantly nuclear

Transcriptional activation/repression

TRβ2

Predominantly nuclear

Transcriptional activation/repression

TRβ2

Predominantly nuclear

Possible transcriptional regulation

TRβ3

Predominantly nuclear

Transcriptional activation/repression

TR∆β3
TRβ4

Predominantly nuclear
Predominantly nuclear

Dominant negative antagonist
Weak antagonist of TR action

TRβ (NR1A2)
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Abstract

Thyroid hormone receptor (TR) is responsible for mediating the expression of genes
involved in growth, development, and homeostatic regulation, in response to thyroid
hormone. There are two main subtypes of TR, TRα1 and TRβ1, that mediate these
physiological processes. Dysregulation of TR mediated processes is a contributing factor
in disease pathology. Our prior studies show that TR is shuttled rapidly between the
nucleus and cytosol, while localizing primarily to the nucleus. TRα1 contains two nuclear
localization signals (NLSs) that act together to confer strong nuclear localization, while
TRβ1 only contains one NLS (NLS-1). Recently, we found that the intracellular
localization of TR is regulated, in part, by post-translational modification of lysines within
NLS-1 by acetylation. We constructed GFP or mCherry-tagged TRα1 and TRβ1
acetylation-mimic and nonacetylation-mimic (unable to be endogenously acetylated)
expression plasmids, transfected them into HeLa cells, and used fluorescence
microscopy to determine the nuclear/cytosolic (N/C) ratio of the mutant receptors by
measuring fluorescence intensity. Data show that the TR acetylation mimic has a
significantly lower N/C ratio compared to wild-type TR, indicating a striking decrease in
nuclear localization, whereas the TR nonacetylation mimic’s N/C ratio was the same as
wild-type TR. Previously, we showed that TR nuclear import is mediated by importins 7,
β1, and α1. We hypothesized that acetylation state alters either TR’s ability to bind
importins or its intranuclear mobility, and that inhibition of the acetyltransferase
CBP/p300 would lead to enhanced TR nuclear localization, while inhibition of the
deacetylase SIRT1 would lead to TR cytoplasmic localization. Using GFP-Trap coimmunoprecipitation, we found that importins 7, β1, and α1 interact with both the TRα1
acetylation and nonacetylation mimics, suggesting that the TRα1 acetylation mimic’s
decreased nuclear localization is due to factors other than reduced importin binding.
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Intriguingly, fluorescence recovery after photobleaching (FRAP) revealed that the GFPTRα1 nonacetylation mimic has a significantly slower rate of recovery than wild-type
TRα1, suggesting that this reduced mobility correlates with greater nuclear retention. In
contrast, the GFP-TRα1 acetylation mimic had the same rate of recovery as wild-type
TRα1. Lastly, pharmacological inhibition of CBP/p300 by C646 increased GFP-TRβ1’s
nuclear localization in a dose-dependent manner (GFP-TRβ1 has a slight cytosolic
population due to having one NLS); however, inhibition of SIRT1 by EX-527 did not alter
GFP-TRα1’s localization. Taken together, these data provide further evidence that
acetylation plays a key regulatory role in TR shuttling and retention and extends our
understanding of how acetylation interplays with TR-regulated processes of growth and
development.

Introduction

The thyroid hormone receptor (TR) is a transcription factor that, through the action of
thyroid hormone, regulates the activity of numerous physiological processes, including
metabolism, cellular growth and proliferation, and survival (Anyetei-Anum, et al. 2018;
Guigon and Cheng 2009). The extensively characterized subtypes of TR, TRα1 and
TRβ1, are encoded by two genes (THRA and THRB) located on human chromosomes
17 and 3, respectively (Kim and Cheng 2013). TRs belong to a large, evolutionarily
conserved superfamily of nuclear receptors that function as ligand-regulated
transcriptional activators or repressors (Taylor and Heyland 2017; Wang, et al. 2011).
The role of TR as a transcription factor is, in part, dependent on its nucleocytoplasmic
shuttling. We have shown that nuclear entry of TRα1 occurs through interactions with
importin 7, importin β1, and adapter importin α1, at the lysine and arginine-rich nuclear
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localization signal (NLS) motifs termed NLS-1 and NLS-2 in the hinge and A/B domains,
respectively (Anyetei-Anum, et al. 2018; Mavinakere, et al. 2012; Roggero, et al. 2016).
Both TRs influence gene expression by binding to target DNA sequences known as
thyroid hormone response elements (TREs), to impact the organization and posttranslational modification (PTM) of nearby histones (Suh, et al. 2013).
One of the most frequently post-translationally modified residues is lysine, which
is targeted by various PTMs, including sumoylation, ubiquitination, and acetylation (Yang
and Seto 2008). Among these PTMs, evidence is accumulating that lysine acetylation
can regulate transcription factor activity by modulating DNA binding, protein-protein
interactions, and intracellular localization (W. Cui, et al. 2016; Glozak, et al. 2005;
Pougovkina, et al. 2014; Sanchez-Pacheco, et al. 2009; Simic, et al. 2015; Soutoglou, et
al. 2000; Wilson, et al. 2010). The acetyltransferase CBP/p300 has been shown to
acetylate TRβ1 (Lin, et al. 2005) and TRα1 (Sanchez-Pacheco, et al. 2009), and the
deacetylase SIRT1 deacetylates TRβ1 (Suh, et al. 2013). TRβ1 acetylation occurs within
the hinge domain at residues K184, K188, and K190 in human TRβ1; and TRα1 is
acetylated at residues K130, K134, and K136, also located within the hinge domain (Lin,
et al. 2005; Sanchez-Pacheco, et al. 2009). Based on these prior reports of acetylated
lysine residues within the hinge domain NLS-1 of TRβ1 and TRα1, we sought to
determine the role of lysine acetylation in TR’s intracellular localization
In the present study, we provide further evidence that TR is acetylated in vivo by
using TRα1 and TRβ1 acetylation/nonacetylation-mimic substitution mutations, GFPTRAP coimmunoprecipitation, FRAP in live HeLa cells, and inhibition of CBP/p300 using
the CBPp300-specfic inhibitor C646 to establish an important role for acetylation in TR
intracellular localization and intranuclear mobility. We demonstrate that the TR
acetylation-mimic substitution mutations within NLS-1 promotes cytosolic localization,
while the TR nonacetylation-mimic has reduced intranuclear mobility. These results
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suggest that local conformational changes within NLS-1 may regulate interactions
between importins, DNA, and/or other binding partners. Collectively, our data support a
model in which acetylation within NLS-1 of TR acts to release TR from DNA or
dimerization partners bound to DNA, pointing to a potential regulatory mechanism for
fine-tuning thyroid hormone induced gene expression.

Methods
Plasmids and subcloning

The expression vectors for enhanced GFP and mCherry, EGFP-C1 and
mCherry-C1, were obtained from Clontech Laboratories, Inc. (Mountain View, CA).
pGFP-TRα1 encodes functional green fluorescent protein (GFP)-tagged human TRα1,
and the plasmid GFP-TRβ1 encodes a GFP-tagged human TRβ1 (Mavinakere, et al.
2012). pmCherry-TRα1 and pmCherry-TRβ1 encode a functional red fluorescent protein
(mCherry)-tagged human TRα1/TRβ1 fusion protein. Plasmids corresponding to the
TRα1 and TRβ1 acetylation mimic (lysine to glutamine substitutions), and nonacetylation
mimic (lysine to arginine substitutions) were synthesized by GeneArt, Inc. (Burlingame,
CA). Preparation of the GFP-TRα1-acetylation/nonacetylation mimic, GFP-TRβ1acetylation/nonacetylation mimic, mCherry-TRα1-acetylation/nonacetylation mimic, and
mCherry-TRβ1-acetylation/nonacetylation mimic expression vectors were performed by
subcloning into the EGFP-C1 and mCherry-C1 vectors. The GFP- and mCherry-TRα1acetylation/nonacetylation mimics were prepared by Cyril Anyetei-Anum (Anyetei-Anum
2016). BglII and KpnI restriction digest enzymes obtained from New England Biolabs,
Inc. (Ipswich, MA) were used for subcloning. The fluorescent-tagged TRβ1 acetylation
and nonacetylation mimic expression plasmids were then transformed into E. coli-DH5α
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subcloning efficient bacteria obtained from New England Biolabs, and purified using
ZymoPURE™ Plasmid Midiprep Kit, Zymo Research Corporation (Irvine, CA) per the
manufacturer’s instructions. Plasmid concentration was determined by UV spectroscopy
with the NanoDrop® ND-1000 full-spectrum UV/Vis Spectrophotometer, and final
constructs were verified by gene sequencing on the departmental ABI PRISM® 3700
Genetic Analyzer.

Cell culture, transient transfection, and drug treatments

HeLa cells (American Type Culture Collection [ATCC], # CCL-2) were cultured
in Minimum Essential Medium (MEM) supplemented with 10% fetal bovine serum (FBS)
(Life Technologies, Grand Island, NY) at 37ºC under 5% CO2 and 98% humidity. Cells
were grown to approximately 80% confluency, then displaced with 0.25% trypsin (Gibco)
before transient transfection procedures. Cells were seeded at a density of ~ 2-3 x 105
cells per well on 22 mm coverslips (Fisher Scientific, Pittsburgh, PA) in 6 well culture
dishes. Twenty-four hours post-seeding cells were transfected with 2 µg of wild-type
GFP- or mCherry-TRα1/TRβ1, TRα1-acetylation/nonacetylation mimic, or TRβ1acetylation/nonacetylation mimic expression plasmids using Lipofectamine 2000 (Life
Technologies). The transfection medium was replaced with fresh MEM containing 10%
FBS at 6 hours post-transfection. Approximately 18 hours later, cells were fixed in 3.7%
formaldehyde, and coverslips were mounted with Fluoro-Gel II mounting medium
(Electron Microscopy Sciences, Hatfield, PA) containing the DNA counter stain 4´,6diamidino-2´-phenylindole dihydrochloride (DAPI, 0.5µg/ml). Cells were then analyzed
for the cellular localization of GFP or mCherry-TRα1/TRβ1 or acetylation/nonacetylation
mimics by fluorescence microscopy. Drug treatments and co-transfection experiments
were similarly prepared. However, for co-transfection experiments 1 µg of wild-type or
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acetylation/nonacetylation expression plasmid were transfected into cells either alone
(GFP or mCherry) or together (GFP and mCherry). For T3 hormone treatment, the
transfection medium was replaced with MEM containing 10% charcoal-stripped FBS
(minus T3) where 100 nM T3 (plus T3) could then be added, as described (Bondzi, et al.
2011; Subramanian, et al. 2015). In the pharmacological inhibition experiments, cells
were treated with the CBP/p300-specific inhibitor C646 (4-24 µM, Sigma) (Bowers, et al.
2010; Gao, et al. 2013), the SIRT1-specific inhibitor EX-527 (0.5-1 µM, Sigma) (Gertz, et
al. 2013; Kawai, et al. 2011), and the general deacetylase inhibitor Trichostatin A (TSA)
(4 nM, Sigma) (W. Cui, et al. 2016). All drug treatments were for approximately 18 hours
post replacement of the transfection mixture (Roggero, et al. 2016; Subramanian, et al.
2015).

Quantitative analysis by fluorescence microscopy and statistical analysis

An inverted Nikon ECLIPSE TE2000-E fluorescence microscope (Nikon
Ultraviolet Excitation: UV-2E/C filter block for DAPI visualization; Blue Excitation: B-2E/C
filter block for GFP visualization; Red Excitation: T-2E/C filter block for mCherry
visualization) was used with a Nikon Plan Apo 40x/0.75 objective. A CoolSNAP HQ2
CCD camera (Photometrics, Tucson, AZ) and NIS-Elements AR software (Nikon) was
used for image acquisition, primary image processing, and quantitative analysis.
Quantitative analysis was based on the utilization of region of interest (ROI) squares to
compare the fluorescence intensity between the nucleus and cytoplasm of the cell. A
minimum of three biologically independent replicates with 100 ROI-analyzed cells were
measured for each transient transfection experiment. Relative nuclear to cytoplasmic
(N/C) distribution and analysis was then calculated and/or normalized in Excel. For
normalization analysis, a N/C ratio greater than a normalized value of 1 was interpreted
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as having a more nuclear distribution, whereas less than 1 indicated a greater
cytoplasmic distribution. Each cell N/C analysis was performed blind, without prior
knowledge of the treatment. The slide’s original labels were removed and replaced with
unrelated naming categories by another laboratory member, who made a key and kept it
secure until N/C analysis was completed. Data were presented as bar graphs with the
bars indicating the mean, or normalized, N/C ratio in a given treatment. Error bars
indicate plus or minus the standard error of the mean (±SEM). Statistical differences
between two groups were determined using an unpaired Student’s t test with two-tailed
P value. Results were considered significant at P < 0.05.

Confocal fluorescence recovery after photobleaching (FRAP)

Twenty-six hours post-transfection, HeLa cells were washed with Dulbecco’s
phosphate buffered saline (D-PBS). Cells were then incubated in 2 mL of MEM-α
medium (nucleosides, no phenol red) for the duration of the assay. After the addition of
MEM-α, plates were incubated in an OkoLab Incubation System (Warner Instruments,
Inc., Hamden, CT) which maintained conditions at 37oC and 5% CO2. A Nikon A1Rsi
confocal microscope Ti-E-PFS (Nikon Inc., Melville, NY) with a 60x oil objective was
used for all FRAP experiments. The 488-nm line of krypton-argon laser with a band-pass
of 525/50 nm emission filter was used for GFP detection. A solid-state 405-nm line of
laser with a band-pass of 450/50 emission filter was used exclusively for photobleaching.
The “Perfect Focus System” (PFS) was applied during the duration of the experiments.
Both acquisition and photobleaching were coordinated within NIS-Elements AR (Nikon).
Using the stimulation module of NIS-Elements, the total experimental time for the assay
was approximately 35 seconds (s). The time was divided into a 5 s “pre-bleach”
acquisition phase at ~2-3% laser power, 1 s of photobleaching at 100% laser power, and
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a post-bleach acquisition phase at ~2-3% laser power. All image acquisition was
conducted through resonant scanning. Data from at least three biological independent
replicates of 20 nuclei (or cytoplasm with the exclusion of nuclei) from separate cells
were recorded for GFP-TRα1 and GFP-TRβ1 and the acetylation/nonacetylation mimics.
FRAP data were normalized from the values 0 – 1, where 0 was the lowest relative
fluorescent intensity directly after the photobleaching phase, and 1 was the highest
relative fluorescent intensity during post-bleach recovery. Normalized data were then
used to calculate the rate of recovery for each experiment. The recovery rate, postbleach fluorescence recovery over time to equilibrium, was used as the primary
measurement to evaluate changes in mobility. The normalized data were used to
estimate a half-time value, i.e. the time required for half of the total fluorescence to
recover back into the bleached region. Mobile and immobile fractions were also
calculated to support our understanding of the mobility dynamics of GFP-TR and the
acetylation/nonacetylation mimics (Femia 2017; Subramanian, et al. 2015).

GFP-TRAP®_A coimmunoprecipitation and western blotting

HeLa cells were seeded on 100 mm vented plates at a concentration of
approximately 11.0 x 105 cells per plate in 10% FBS-MEM. Twenty-four hours postseeding, each plate was transfected with expression plasmids encoding GFP, GFPTRα1, GFP-TRα1-nonacetylation mimic, GFP-TRα1-acetylation mimic, GFP-TRβ1nonacetylation mimic, or GFP-TRβ1-acetylation mimic, using Lipofectamine 2000. After
26 hours, cells were washed with ice-cold D-PBS, treated for 1 min with 1 ml of 0.25%
trypsin (Life Technologies), collected in 1.0 ml 10% FBS-MEM, then transferred to 2.0 ml
microcentrifuge tubes. Cells were washed 2X with D-PBS, then lysed in 200 μl of Lysis
Buffer (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 0.5 mM EDTA) containing 0.5% IGEPAL
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(NP-40 equivalent, Sigma-Aldrich) and 1X Halt Protease Inhibitor Cocktail (Thermo
Scientific). Cells were incubated for 30 min on ice, with thorough pipetting every 10 min.
The lysate was cleared by centrifugation at 4°C, 16,000 x g for 10 min, and the
supernatant concentration was determined using NanoDrop® ND-1000 full-spectrum
UV/Vis Spectrophotometer. The supernatant was transferred to a new tube and diluted
with 300 μl of Dilution/Washing Buffer (2 mM Tris-HCl, pH 7.5, 30 mM NaCl, 0.1 mM
EDTA), containing 1X Halt Protease Inhibitor Cocktail, to yield a final concentration of
0.2% IGEPAL. GFP-trap agarose beads (GFP-Trap®_A, Chromotek GmbH, PlaneggMartinsried, Germany) were pre-equilibrated by washing 3X with Dilution/Washing
Buffer, then 20 μl were added to each diluted supernatant. After 2.5 h of incubation at
room temperature with end-over-end rotation, beads were centrifuged at 4°C, 3000 x g
for 4 min. A 50 μl sample of the supernatant (unbound proteins) was collected and
resuspended with an equal volume of 2X Sample Buffer (2% SDS, 10% glycerol, 250
mM Tris-HCl, pH 6.8, 0.01% bromophenol blue, 20 mM DTT). The beads were washed
3X with 100 μl Dilution/Washing Buffer lacking IGEPAL, then resuspended in 100 μl of
2X Sample Buffer. Samples of unbound and bound proteins (20 µl) were separated by
12% SDS-PAGE and transferred to PVDF membrane using the iBlot Dry Blotting System
(Life Technologies). The membranes were incubated overnight at 4oC in blocking
solution (Tris-buffered saline containing 0.1% Tween 20 [T-TBS], 1% bovine serum
albumin). Ponceau S solution (0.1 % [w/v] in 5% acetic acid, Sigma) was used prior to
western blotting for total protein staining. The membranes were washed with T-TBS,
then immersed in 10 ml Ponceau S solution for ~5 min. The proteins were visualized as
red/pink bands on the membrane after washing 3X for 5 min each with deionized H2O.
Stained membranes were quantified by scanning densitometry using NIH ImageJ
software. For de-staining, the membranes were immersed in 0.1 M NaOH; the red/pink
bands began to disappear after ~ 30 sec. The membranes were rinsed in deionized H2O
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for 3 min for complete de-staining. After 6 washes with T-TBS at room temperature, the
membranes were then incubated with primary antibodies for 2 hours. Blots were washed
6X with T-TBS and incubated with the appropriate secondary antibody for 1.25 hours in
blocking solution. Subsequently, blots were washed 6-8 times in T-TBS, followed by
chemiluminescent detection using ECL Prime detection reagent (GE Healthcare Life
Sciences). Antibodies were used at the following concentrations: anti-GFP (Santa Cruz),
1:2000; anti-importin 7 (Abcam), 1:1000; anti-importin β1 (Santa Cruz), 1:1000; antiimportin α1 (Abcam), 1:1000; horseradish peroxidase (HRP)-conjugated donkey antirabbit IgG (GE Healthcare Life Sciences), 1: 25,000; or HRP-sheep anti-mouse IgG
(Santa Cruz). Protein size was confirmed using Pre-Stained Kaleidoscope Protein
Standards (Bio-Rad, Hercules, CA). X-ray films were quantified by scanning
densitometry using NIH ImageJ software.

Results

Acetylation alters TRα1 and TRβ1 intracellular localization in HeLa cells

In previous studies, it was shown that TRα1 and TRβ1 are acetylated at lysines
130, 134, and 136 (TRα1), and lysines 184, 188, and 190 (TRβ1) by CBP/p300 in vitro;
moreover, the use of anti-acetyl lysine antibodies showed that TR acetylation occurs in
cultured cells after exposure to thyroid hormone (T3 or T4) (Lin, et al. 2005; SanchezPacheco, et al. 2009). Given that acetylation occurs within the hinge domain NLS-1, we
examined the role of acetylation in TR’s intracellular localization by point mutation
substitutions introduced into wild-type TRα1 and TRβ1. Because acetylation of lysine (a
positively charged-hydrophobic residue) both reduces its charge and increases its
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polarity, it is well-established that mutation of the three acetyl lysines in NLS-1 to a polar
(glutamine/Q) and a positively charged residue (arginine/R) may serve as an acetylation
mimic and nonacetylation mimic, respectively. The human GFP or mCherry-TRα1
K130/134/136Q (or R), and GFP or mCherry-TRβ1-K184/188/190Q (or R) constructs
were unable to be endogenously acetylated, as previously confirmed (SanchezPacheco, et al. 2009). Also, both GFP and mCherry-tagged constructs were made to
ensure the reproducibility of results in either fluorescent protein. We transfected the
mCherry-TRα1, mCherry-TRα1-nonacetylation mimic, mCherry-TRα1-acetylation mimic,
or empty mCherry expression plasmids into HeLa cells that lack endogenous TR (Bunn,
et al. 2001) and showed by quantitative fluorescence microscopy that the mCherryTRα1-acetylation mimic has a significantly reduced nuclear localization compared to
wild-type or the nonacetylation mimic (Fig. 1, A and B; P = 0.028), these results are
previously described in Cyril Anyetei-Anum’s Honors Thesis (Anyetei-Anum 2016). We
conducted a similar experiment for GFP-TRβ1, GFP-TRβ1-nonacetylation mimic, and
the GFP-TRβ1-acetylation mimic, and found that the GFP-TRβ1-acetylation mimic
nuclear localization was significantly reduced (Fig. 2, C and D; P = 0.013). To confirm
whether the report of acetylated TRα1 dominant-negative activity on wild-type TRα1
transcriptional activity (Sanchez-Pacheco, et al. 2009) carried over to TRα1’s transport
activity, we co-transfected wild-type mCherry-TRα1 with GFP-TRα1-nonacetylation
mimic, or wild-type GFP-TRα1 with mCherry-TRα1-nonacetylation mimic. We observed
no effect on wild-type TRα1 localization (Fig. 1E; P = 0.767). In addition, preliminary data
of co-transfection experiments with wild-type TRα1 and the TRα1-acetylation mimic
show no observable dominant negative effect; i.e. the distribution of wild-type TRα1
remained primarily nuclear. With the more cytosolic population of the TRα1 and TRβ1acetylation mimics established, we next wanted to determine whether thyroid hormone
(T3) altered this distribution. HeLa cells were transfected with wild-type mCherry-TRα1 or
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mCherry-TRα1-acetylation mimic and treated with or without 100 nM T3 for 18 hours.
The data show that T3 has no effect on the intracellular distribution of the TRα1acetylation mimic (Fig. 1F; P = 0.151); however, there was a significant liganddependent increase in nuclear localization for wild-type mCherry-TRα1 (Fig. 1F; P =
0.039). Previous data from Anyetei-Anum’s Honors Thesis (Anyetei-Anum 2016) with
the TRα1-nonacetylation mimic showed no change in its nuclear localization after T3
exposure. This increase in nuclear localization may be due to T3-induced nuclear import
of the wild-type TRα1. These results reveal that TRα1 and TRβ1 acetylation within NLS1 decreases their nuclear localization, and suggest that the acetylation mutant has no
dominant negative effects on the transport activity of wild-type TR.

Importin 7, importin β1, and importin α1 interact with the TRα1 acetylation mimic

Our prior study showed that importin 7, importin β1, and importin α1 interact with
TRα1; whereas, importins β1 and α1 interact with TRβ1 (Roggero, et al. 2016). Since the
TRα1 and TRβ1-acetylation mimics maintained a nuclear population, we sought to
determine whether the acetylation mimic’s significant cytosolic population was due to
impaired binding with the importins. We predicted that the TRα1 and TRβ1-acetylation
mimics would have reduced binding to importins compared to the wild-type receptor for
the following reason. A previous report indicated that acetylation of the adenovirus E1A
transforming protein abrogates interaction with importin-α3 (Madison, et al. 2002).
Although they used a different importin, the mechanistic action of acetylation neutralizing
the positive charge on lysine remains the same. To confirm that importin 7, importin β1,
and importin α1 interact with TRα1, TRβ1 and the acetylation and nonacetylation mimics
in vivo, we performed “GFP-trap” coimmunoprecipitation assays on lysates from HeLa
cells that had been transfected with expression plasmids for GFP, GFP-TRα1, GFP62

TRα1-acetylation or nonacetylation mimic, GFP-TRβ1, GFP-TRβ1-acetylation or
nonacetylation mimic (Fig. 2). We confirmed that the aforementioned expression
plasmids were all successfully immunoprecipitated by the GFP-trap assay, by
immunoblot analysis of immunoprecipitate samples with anti-GFP antibodies; in addition,
Ponceau S solution was used to determine total protein present (Fig. 2A). Samples of
unbound proteins (immunosupernatant) and bound proteins (immunoprecipitates) were
analyzed for the presence of importins 7, β1, and α1 on separate blots using importinspecific antibodies (Fig. 2, B and C). Endogenous importin 7, importin β1, and importin
α1 were successfully coimmunoprecipitated (trapped) with GFP-TRα1, GFP-TRα1acetylation mimic, and the GFP-TRα1-nonacetylation mimic, and not with GFP. Importin
β1 and importin α1 were trapped with GFP-TRβ1, GFP-TRβ1-acetylation mimic, and the
GFP-TRβ1-nonacetylation mimic and not with GFP. Binding affinities between GFPTRα1, GFP-TRα1-acetylation/nonacetylation mimics and importins were measured by
densitometry analysis; there was no significant change in importin 7 (P = 0.694) binding
GFP-TRα1, and importin β1 (P = 0.273) indirectly binding through the adapter importin
α1. The GFP-TRα1-acetylation mimic showed a significant increase in binding importin
α1 (P = 0.046) (Fig. 2B). There was no significant change in importin α1 (P = 0.133)
binding GFP-TRβ1 and the acetylation mimic. However, there was a significant increase
in the GFP-TRβ1-acetylation mimic’s ability to indirectly bind importin β1 through the
adapter importin α1 (P = 0.033) (Fig. 2C). Importin binding with the TRα1 and TRβ1nonacetylation mimics was not significantly different from wild-type binding (P > 0.200). It
is likely that the increase seen in importin α1 binding the GFP-TRα1-acetylation mimic,
and importin β1 indirectly binding the GFP-TRβ1-acetylation mimic is due to a lot of
variability as indicated by the error bars. Taken together, these data provide evidence
that acetylation does not inhibit interactions with importins 7, β1, and α1 in vivo.
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The TRα1 and TRβ1 nonacetylation mimics have reduced intranuclear mobility

Having shown that TRα1 and TRβ1 acetylation within NLS-1 of the hinge domain
causes a dramatic shift in localization to the cytoplasm that is not due to reduced
importin binding, the question still remained of whether other pathways could explain the
acetylation mimic’s cytosolic localization. Given that the acetylated residues are adjacent
to the DNA binding domain (DBD)--which forms heterodimer-specific contacts with the
DBDs of other transcription factors such as RXR DBD (Nascimento, et al. 2006), we
predicted that acetylation may act to increase TR’s intranuclear mobility by affecting
wild-type TR’s interaction with RXR, or the peroxisome proliferator activated receptor γ
coactivator 1α (PGC-1α) (Suh, et al. 2013); thus, explaining the acetylation mimic’s
cytosolic localization. To analyze intranuclear mobility, we used a variation of FRAP,
termed strip-FRAP. Strip-FRAP was selected as the method of choice based on the
smooth distribution of TR in the nucleus. In this method, a small strip through the
nucleus is photobleached and mobility is monitored by the recovery of fluorescent
proteins into the bleached strip. The validity of our FRAP experiments have been
previously confirmed (Femia 2017).
To begin, we compared live HeLa cells expressing GFP-TRα1 or GFP-TRβ1, to
cells expressing their corresponding nonacetylation or acetylation mimics (Fig. 3, A and
B). The fluorescence intensity data revealed a startling, marked reduction in the GFPTRα1-nonacetylation (P = 0.042), and GFP-TRβ1-nonacetylation mimics (P = 0.007)
intranuclear mobility compared to wild-type GFP-TRα1 and GFP-TRβ1. The GFP-TRα1acetylation mimic’s intranuclear mobility was the same as wild-type GFP-TRα1 (P =
0.106), but the GFP-TRβ1-acetylation mimic’s intranuclear mobility was significantly
slower compared to wild-type GFP-TRβ1 (P = 0.047). The GFP-TRβ1-acetylation
mimic’s significantly slower intranuclear mobility is due to TRβ1’s intrinsically variable
64

localization pattern (in part due to having one NLS), therefore a greater sample size will
reduce this variability. Next, we compared the cytoplasmic mobility of the GFP-TRβ1acetylation mimic to that of wild-type GFP-TRβ1 to confirm the similarities between the
wild-type and acetylation mimic mobilities. We found that both the cytoplasmic and
intranuclear mobilities were comparable (Fig. 3C; P = 0.878).
Interestingly, the GFP-TRα1-nonacetylation and GFP-TRβ1-nonacetylation
mimics have a significant discrete, punctate appearance (P = 0.0002) reminiscent of
ligand-induced intranuclear reorganization of GFP-ER (Maruvada, et al. 2003) and
yellow fluorescent protein (YFP)-tagged GR (Schaaf, et al. 2005) that is indicative of
transcriptional activity (Fig. 4). Our finding of intranuclear reorganization suggests the
possibility that GFP-TRα1-nonacetylation and GFP-TRβ1-nonacetylation mimics may
interact with other nuclear receptors, chromatin, or the nuclear matrix to reduce their
intranuclear mobility. This is in accordance with previous studies that show via band-shift
assays that the TRα1-nonacetylation mimic has increased binding to TREs (SanchezPacheco, et al. 2009), and demonstrate by FRAP that the intranuclear mobility and
reorganization of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B
cells) subunit p65 is determined by its affinity for specific DNA sequences (Schaaf, et al.
2006). Slope, mobile fraction, immobile fraction, estimated half-time, and intranuclear
reorganization data are presented in Table 1. The results presented here highlight the
complexity of TR acetylation and provide further evidence of a role for acetylation in
promoting cytosolic localization of this receptor, either through direct interactions with
acetyltransferases or indirect mechanisms of protein-protein interaction.
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Inhibition of the acetyltransferase CBP/p300 by C646 promotes TRβ1 nuclear retention

The preceding results suggest that acetylation may act as a regulatory
mechanism for TRα1 or TRβ1 release from DNA or heterodimerization partners (such as
RXR or PGC-1α) in the nuclear compartment. Since TRβ1 does not contain an
additional NLS (NLS-2) in the A/B domain, that is present in TRα1, TRβ1 typically has a
small cytosolic population at steady-state (Mavinakere, et al. 2012). We primarily
focused on TRβ1 in our analysis to provide evidence on whether acetylation occurs in
the nucleus. To test this, we used C646, a pharmacological inhibitor of the
acetyltransferase CBP/p300. We predicted that if acetylation occurs in the nucleus, there
would be a decrease in TRβ1’s cytosolic population due to CBP/p300 inhibition. As
predicted, inhibition of the acetyltransferase CBP/p300 by C646 in GFP-TRβ1
expressing HeLa cells caused a significant dose-dependent increase in GFP-TRβ1’s
nuclear localization at 16 µM C646 (P = 0.029), and 24 µM C646 (P = 0.007) (Fig. 5A).
Verifying the TR-nonacetylation mimic’s nuclear localization. At higher C646 exposure
levels, cell viability decreased.
We also examined the effects of TSA, a general deacetylase inhibitor. We
predicted that deacetylation would occur in the cytoplasm, to promote re-entry of the
originally acetylated TR to the nucleus. Contrary to our prediction, TSA caused a
significant increase in GFP-TRβ1’s nuclear localization (P = 0.020) (Fig. 5B). A possible
reason for the increase in nuclear localization for GFP-TRβ1 could be due to TSA
induced histone acetylation (Xu, et al. 2018) and subsequent binding of TRβ1 to TREs in
exposed DNA.
In a second approach, we investigated whether SIRT1 inhibition by the SIRT1
deacetylase inhibitor EX-527 would result in a cytosolic shift in localization for GFPTRβ1 or GFP-TRα1. The rationale was that a prior study found that inhibition of SIRT1
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increased the cytosolic localization of the transcription factor Sox9 (Bar Oz, et al. 2016).
Sox9 was found to have reduced nuclear entry when acetylated by CBP/p300 at K75,
and is deacetylated by SIRT1 (Bar Oz, et al. 2016). Inhibition of the TR-specific SIRT1
deacetylase had no noticeable effect on either GFP-TRβ1 (P ≥ 0.147) or GFP-TRα1’s (P
≥ 0.917) intracellular localization (Fig. 5C). This may be due to redundancy in the sirtuin
deacetylase family (Ali, et al. 2018), with one of the seven sirtuin proteins acting as a
potential backup. Further analysis of sirtuin family inhibition is needed to provide support
for our prediction; however, this approach may lead to decreased cell viability because
the use of drug inhibitors may have off-target effects.

67

A

B

68

C

D

69

E
14
12

N/C Ratio

10
8
6
4
2
0
mCherry-TRα1

GFP-TRα1nonacetylation
mimic

GFP-TRα1

mCherry-TRα1- cotransfected- cotransfected- cotransfected- cotransfectednonacetylation mCherry-TRα1
GFP-TRα1GFP-TRα1
mCherry-TRα1mimic
nonacetylation
nonacetylation
mimic
mimic

F

Figure 1. Acetylation substitution mutation within NLS-1 alters TRα1 and TRβ1
intracellular localization. (A) HeLa cells transfected with mCherry, mCherry-TRα1, and
mCherry-TRα1-nonacetylation or acetylation mimic expression plasmids were analyzed
by quantitative fluorescence microscopy after staining with DAPI to visualize the
nucleus. (B) Corresponding bar graphs for the image panel. Data from Anyetei-Anum’s
Honors Thesis. (C) HeLa cells transfected with GFP-TRβ1 and GFP-TRβ1nonacetylation or acetylation mimic expression plasmids. (D) Corresponding bar graphs
for the image panel. (E) HeLa cells co-transfected with wild-type mCherry-TRα1 (red)
and GFP-TRα1-nonacetylation mimic
(continued on next page)
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(green squares), or wild-type GFP-TRα1 (green) with mCherry-TRα1-nonacetylation
mimic (red squares). Green squares against a red background represent co-transfection
of the corresponding expression plasmids, and vice versa. Data from Anyetei-Anum’s
Honors Thesis, P > 0.05. (F) HeLa cells transfected with mCherry-TRα1 or mCherryTRα1-acetylation mimic and treated with or without 100 nM T3 for 18 hours. Region of
interest squares were used to compare relative fluorescence intensity between the
nucleus and cytoplasm (N/C) to determine average fluorescence intensity for all graphs.
Bars indicate the nuclear/cytosolic ratio of TR (n=3 independent, biologically separate
replicate experiments, with 100 cells per replicate), and error bars indicate ± SEM (*=P ≤
0.05, n.s.=P > 0.05; student’s t-test).
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Figure 2. Importin 7, importin β1, and importin α1 coimmunoprecipitate with GFP-TRα1
and the acetylation/nonacetylation mimics; and importin β1 and adapter importin α1
coimmunoprecipitate with GFP-TRβ1 and the acetylation/nonacetylation mimics. HeLa
cells were transfected with expression plasmids encoding GFP (27 kDa), GFP-TRα1 (73
kDa), GFP-TRα1-acetylation or nonacetylation mimic (73 kDa), GFP-TRβ1 (79 kDa),
GFP-TRβ1-acetylation or nonacetylation mimic (79 kDa), as indicated. Cell lysates were
subjected to coimmunoprecipitation using immobilized anti-GFP-antibodies (GFPTRAP®_A). Representative immunoblots, and corresponding densitometry graphs are
shown. Error bars indicate ± SEM (n = 3 independent, biologically separate replicate
experiments). Protein size was verified using Pre-stained Kaleidoscope protein
standards. (A) Trapped GFP-tagged proteins were analyzed by immunoblotting with
antibodies specific for GFP. The two lower molecular weight bands in the GFP-TRα1,
GFP-TRα1-nonacetylation/acetylation mimic lanes represent specific degradation
products.
(continued on next page)
73

Ponceau S staining revealed a ~20 kDa protein band used for densitometry analysis in
ImageJ. (B) Immunosupernatants (Unbound) and immunoprecipitates (Bound) from
GFP, GFP-TRα1, GFP-TRα1-acetylation or nonacetylation mimic-expressing, and GFP,
GFP-TRβ1, GFP-TR β1-acetylation or nonacetylation mimic-expressing (C) cell lysates
were analyzed on separate immunoblots (using longer exposure times for the
immunoprecipitates), with importin-specific importins to detect importin 7 (119 kDa),
importin β1 (97 kDa), and importin α1 (58 kDa), as indicated. *=P ≤ 0.05.
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Figure 3. The GFP-TRα1 and GFP-TRβ1 nonacetylation mimics have reduced
intranuclear mobility. HeLa cells were transfected with expression plasmids encoding
GFP-TRα1 (A), GFP-TRβ1 (B), and their corresponding acetylation and nonacetylation
mimics, as indicated. Strip-FRAP was conducted on nuclei from 20 separate cells using
a stimulation bleaching line near the middle of the nuclei. (C) HeLa cells were
transfected with expression plasmids encoding GFP-TRβ1, and the GFP-TRβ1acetylation mimic. Strip-FRAP was conducted in the cytoplasm from 20 separate cells
using a modified stimulation bleaching line (white arrow heads indicate bleached region).
A minimum of 3 biological replicates were performed (n ≥ 3). Data were normalized. For
intranuclear reorganization statistical analysis, the image’s original labels were removed
and replaced with unrelated naming categories, and laboratory members sorted images
based on punctate appearance. Error bars indicate ± SEM. (*=P ≤ 0.05; student’s t-test).
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Table 1. FRAP measurements for GFP-TRα1, GFP-TRβ1, and the acetylation and
nonacetylation mimics. Slope, mobile and immobile fraction, halftime measurements,
and intranuclear reorganization for GFP-TRα1, GFP-TRβ1, and their corresponding
acetylation and nonacetylation mimics. Data were calculated from FRAP curves for each
separate experiment. Dark blue indicates a statistically significant difference between
GFP-TRα1 and the GFP-TRα1-nonacetylation mimic. Purple indicates a statistically
significant difference between GFP-TRβ1 and the GFP-TRβ1-nonacetylation mimic
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Figure 4. GFP-TRα1 and GFP-TRβ1 and nonacetylation mimic’s intracellular
distribution. HeLa cells were transfected with expression plasmids encoding GFP-TRα1
(A and B), GFP-TRβ1 (C and D), and their corresponding nonacetylation mimics, as
indicated. The left panel shows the smooth distribution pattern of wild-type TR, and the
right panel displays the punctate appearance of the GFP-TR-nonacetylation mimics.
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Figure 5. Inhibition of the acetyltransferase CBP/p300 by C646 promotes TRβ1 nuclear
retention. Fluorescence microscopy was used to analyze the N/C ratio of TR, as
described in Fig. 1. (A) HeLa cells were transfected with GFP-TRβ1 expression plasmid.
Cells were treated with increasing dosage of C646, a CBP/p300-specific
acetyltransferase inhibitor, as indicated. Data were normalized. (B) HeLa cells were
transfected with GFP-TRβ1 or mCherry-TRβ1 expression plasmids. Cells were treated
with 4 nM TSA, a general deacetylase inhibitor. (C) HeLa cells were transfected with
GFP-TRβ1 or GFP-TRα1 expression plasmids. Cells were exposed to 0.5 µM, and 1 µM
Ex-527, a SIRT1-specific deacetylase inhibitor. Data were normalized. For all graphs
n=3 independent, biologically separate replicate experiments, with 100 cells per
replicate. Error bars indicate ± SEM. (*=P ≤ 0.05, n.s.=P > 0.05; student’s t-test).
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Discussion

Our interest for many years has been in the investigation of TR’s balance
between import, export, and nuclear retention. The emerging picture of TR’s subcellular
distribution extends understanding of homeostatic and metabolic processes within
vertebrate tissues. The addition of TR acetylation to this emerging picture provides an
additional checkpoint in the careful coordination of the regulation of protein-protein
interactions, subcellular localization, and cell fate. The dysregulation of lysine acetylation
has been linked to cancer and other diseases (Weinert, et al. 2018). Due to the
structural and functional similarities among nuclear receptors, elucidating the underlying
mechanisms behind TR acetylation is an important endeavor that will contribute to our
overall understanding of nuclear receptor acetylation. Among the acetyl lysine residues
130, 134, and 136 in TRα1, mutation of lysine 136 to arginine has been associated with
Hepatocellular Carcinoma (HCC). Along with three other mutations in the receptor,
serine 40 to threonine, leucine 251 to proline, and valine 390 to alanine (Lin, et al. 1999).
These mutations suggest that dysregulation of TR acetylation contributes to HCC
pathology.
The field of nuclear receptor acetylation is a rapidly advancing and evolving field.
Here, we have investigated the role of acetylation in TRα1 and TRβ1 activity by using
acetylation and nonacetylation-mimic substitution mutations, GFP-TRAP
coimmunoprecipitation, FRAP in live HeLa cells, inhibition of the acetyltransferase
CBP/p300 using the CBPp300-specfic inhibitor C646, and inhibition of the deacetylase
SIRT1 using the SIRT1-specific inhibitor EX-527. We show that the TR acetylation
mimic has a striking decrease in nuclear localization, whereas the TR nonacetylation
mimic has the same nuclear localization as wild-type TR. Moreover, we found that
importins 7, β1, and α1 interact with TRα1 and importins β1 and α1 interact with TRβ1
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acetylation and nonacetylation mimics, suggesting that the TR acetylation mimic’s
decreased nuclear localization is due to factors other than reduced importin binding.
FRAP data revealed that the GFP-TRα1 nonacetylation mimic has a significantly slower
rate of recovery than wild-type TRα1, suggesting that this reduced mobility correlates
with greater nuclear retention. In contrast, the GFP-TRα1 acetylation mimic had the
same rate of recovery as wild-type TRα1. In addition, pharmacological inhibition of
CBP/p300 by C646 increased GFP-TRβ1’s nuclear localization in a dose-dependent
manner (GFP-TRβ1 has a slight cytosolic population due in part to having one NLS)
suggesting that acetylation occurs within the nucleus, but inhibition of SIRT1 by EX-527
did not alter GFP-TRα1’s localization. Our novel findings demonstrate that acetylation is
a contributing factor in TRα1 and TRβ1 nucleocytoplasmic distribution and intranuclear
mobility. That acetylation promotes cytoplasmic localization of both subtypes of TR
points to a potential regulatory mechanism for fine-tuning thyroid hormone-responsive
gene expression.
In the proposed model (Fig. 6), acetylation of TR is induced by its own ligand.
Curiously, TRβ1 acetylation is transient (Lin, et al. 2005) and TRα1 acetylation persists
for a 36-h period (Sanchez-Pacheco, et al. 2009). Acetylation of both TR subtypes
occurs at specific lysine residues located within NLS-1. In its nonacetylated state, TR is
bound to transcriptional corepressors and heterodimerization partners in the absence of
ligand, and has reduced intranuclear mobility. In the presence of ligand, TR is acetylated
by the transcriptional coactivator CBP/p300 and has a hard time remaining in the
nucleus. SIRT1 deacetylates TRβ1, potentially leading to ubiquitin-mediated degradation
(Suh, et al. 2013). The deacetylase that acts on TRα1, and the cellular compartment in
which deacetylation occurs are unknown. Taken together, our results are consistent with
a mechanism in which acetylation within NLS-1 of TR acts as a mechanism to release
TR from DNA.
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Figure 6. Proposed model of acetylation in TR intracellular transport and intranuclear
mobility. (1) Nonacetylated TR is in the nucleus, tightly bound to DNA or a
heterodimerization partner, such as RXR or PGC-1α and, as a result, has reduced
intranuclear mobility. The CBP/p300 acetyltransferase transcriptional coactivator is also
present. (2) In the presence of ligand (T3 or T4), TR is acetylated by CBP/p300 and is
released from DNA and/or heterodimerization partners. T3 enters inside the cell through
the monocarboxylate 8 and 10 transporters (MCT8/10) to induce acetylation of TRα1,
whereas T4 activation of MAPK signaling is implicated in TRβ1 acetylation (Lin, et al.
2005) (3) The acetylated receptor then localizes to the cytoplasm. It may be targeted for
proteasome-mediated degradation, or deacetylated by SIRT1. The cellular compartment
for TR deacetylation remains unknown (as indicated by the question mark).
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Chapter 4: General Discussion and Future Directions

The role of acetylation in the intracellular localization of transcription factors is not
without precedent. The functional role of acetylation in inhibiting or promoting nuclear
import is transcription factor-specific (Soniat, et al. 2016). There is ample evidence for
nuclear import inhibition and accumulation. With regard to nuclear import inhibition, it
has been shown by GST pull-down, isothermal titration calorimetry (ITC), and
acetylation-mimic substitution mutation that acetylation of histones H3 and H4 decreases
interaction with several members of the karyopherin-β family of importins (Soniat, et al.
2016). Also, for the Rho guanine nucleotide exchange factor Net1A it has been shown
via acetylation-mimic substitution mutation and TSA pharmacological inhibition that
acetylation results in its cytoplasmic localization (Song, et al. 2015). In addition, studies
using acetylation-mimic substitution mutation experiments and/or karyopherin binding
assays report on the cytoplasmic accumulation of a number of transcription factors,
including the Signal transducer and activator of transcription 1 (STAT1) (Antunes, et al.
2011) and HDAC6 (Jiménez-Canino, et al. 2016).
For nuclear import accumulation, androgen receptor acetylation at lysine residue
618 by the acetyltransferase ARD1 (Arrest-defective protein 1) results in its translocation
into the nucleus (DePaolo, et al. 2016). In addition, acetylation of the hepatocyte nuclear
factor-4 (HNF-4) NLS results in its nuclear localization (Soutoglou, et al. 2000).
Furthermore, TSA pharmacological inhibition in HeLa cells expressing GFP-class II
transactivator (CIITA) increased the nuclear import of GFP-CIITA (Spilianakis, et al.
2000).
The critical role of lysine acetylation in regulating transcription factor intracellular
localization is apparent, and our findings suggest that acetylation promotes cytosolic
accumulation, but the physiological significance of TR acetylation remains unknown. The
84

notion of an inter-regulated network of PTM’s is gaining traction. A recent study
proposes a mutually exclusive acetylation-sumoylation switch, in which acetylation of the
pregnane X receptor (PXR) is a prerequisite for its subsequent SUMO-modification (Cui,
et al. 2016). This suggests that acetylation of TR may be part of an integrated network of
PTM’s that are responsive to pathological stimuli to coordinate both the induction and
repression of gene expression.

Future Directions

Additional analyses of protein-protein interactions via proximity ligation assay
should help to clarify the issue of importin and acetylation mimic binding. Further
experiments combining pharmacological drug inhibition (i.e. C646) with FRAP will
provide further elucidation of the intranuclear mobility dynamics of wild-type TR vs the
nonacetylation mimic. In addition, verification of the acetylation mimic’s nuclear
population can be done via chromatin immunoprecipitation (ChIP) to determine
interaction with the thyroid hormone response element (TRE). These future experiments
will allow for the conclusive determination of the role of acetylation in TR intracellular
localization and intranuclear mobility.
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